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Prion protein (PrP) is expressed on a wide variety of cells and plays an important 
role in the pathogenesis of transmissible spongiform encephalopathies. However, 
its normal function remains unclear. Mice that do not express PrP exhibit deficits 
in spatial memory and abnormalities in excitatory neurotransmission suggestive 
that PrP may function in the glutamatergic synapse. Here we show that transport 
of D-aspartate, a non-metabolized L-glutamate analog, through excitatory amino 
acid transporters (EAATs) was faster in astrocytes from PrP knockout (PrP KO) 
mice than in astrocytes from C57BL/10SnJ wildtype (WT) mice. Experiments 
using EAAT subtype-specific inhibitors demonstrated that in both WT and PrP 
KO astrocytes, the majority of transport was mediated by EAAT1. Furthermore, 
PrP KO astrocytes were more effective than WT astrocytes at alleviating L-
glutamate-mediated excitotoxic damage in both WT and PrP KO neuronal 
cultures. Thus, in this model, PrP KO astrocytes exerted a functional influence on 
neuronal survival and may therefore influence regulation of glutamatergic 
neurotransmission in vivo. 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 1 
CHAPTER ONE 
INTRODUCTION 
 
 Prion protein (PrP) is expressed in several mammalian tissues and is 
highly expressed in the central nervous system. While the precise function of PrP 
is unknown, studies suggest that PrP plays a role in many aspects of 
neurotransmission mediated by the neurotransmitter L-glutamate. Glutamatergic 
neurotransmission is dependent on L-glutamate availability in the synaptic cleft 
and subsequent activation of L-glutamate receptors. Specificity of activity is 
regulated by excitatory amino acid transporters (EAATs) expressed on neurons 
and astrocytes. The potential role PrP plays in neurotransmission and the pivotal 
role of EAATs in controlling L-glutamatergic neurotransmission provided the 
rationale to studying whether a function of PrP is to regulate concentrations of L-
glutamate through modulation of EAAT activity. 
 
1.1 Prion Protein 
Prion Protein (PrP) is an evolutionarily conserved protein expressed in a 
number of different species including fish, amphibians, birds, cervids, ungulates, 
rodents and primates (Aguzzi et al., 2008). The gene encoding PrP is located on 
chromosome 2 in mus musculus (Prnp) and chromosome 20 in homo sapiens 
(PRNP). In some species, including bovine, deer, elk, mouse, rat and sheep, the 
Prnp gene contains 3 exons, while in other species including hamsters and 
humans, the gene contains 2 exons. Uniquely, the entire reading frame is 
contained in one exon (Basler et al., 1986), which in mice is exon 3. Gene 
expression is controlled by sequences contained in the 5’-flanking region, first 
intron and 3’-untranslated sequences.  
 Similar to other membrane proteins, biosynthesis of PrP begins in the 
rough ER and traffics through the Golgi to its final location on the plasma 
membrane. In the rough ER, PrP is subject to post-translational modifications 
including removal of its N-terminal signal peptide, addition of a C-terminal 
glycosyl-phosphatidylinositol (GPI) anchor, addition of N-linked glycosylations 
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and formation of a disulfide bond. PrP then passes through the Golgi for further 
modifications before reaching the plasma membrane where it exists as a double 
glycosylated protein anchored to the plasma membrane in detergent- resistant 
lipid rafts via the GPI anchor. 
 PrP exists as a disordered amino terminal flexible domain (amino acid 
residues 23-124) and globular carboxyl terminal domain (amino acid residues 
125-226). The N-terminal domain contains a highly conserved octapeptide repeat 
region that is able to bind copper with µM affinity. The C-terminal domain 
contains three alpha helices (amino acid residues 144-154, 173-194 and 200-
220) and an anti-parallel beta sheet formed by beta strands 128-131 and 161-
164. A disulfide bond links cysteine residues 179 and 214.  
 
 
Figure 1.1 Prion Protein. a) NMR solution structure of elk PrP residues 121-231 (adapted from 
(Gossert et al., 2005)).  
 
 While the majority of PrP molecules are at the cell surface, a pool are 
constitutively cycling between the plasma membrane and endocytic 
compartments. Surface iodination of PrP revealed that a population of PrP 
molecules cycle between the plasma membrane and endocytic compartments 
with a transit time of 60 minutes (Shyng et al., 1993).  However the mechanism 
of endocytosis is controversial. Immunogold EM revealed PrP enriched in 
caveolae at the plasma membrane of CHO cells (Peters et al., 2003) suggesting 
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a mechanism involving a caveolae-mediated endosomal pathway. However, 
stronger evidence exists suggesting PrP endocytosis is clathrin-mediated, which 
is unusual for GPI anchored proteins that lack an intracellular sequence 
necessary for interaction with endocytic adaptor proteins. Electron microscopy 
revealing PrP in clathrin-coated vesicles, prevention of internalization by 
disrupting clathrin lattices (Shyng et al., 1994) and studies using cells transfected 
with dynamin mutant K44A  (Magalhaes et al., 2002) strongly suggest clathrin is 
involved in endocytosis. Internalization of GPI anchored PrP may involve usage 
of its positively charged domain (KKRPKP) in the amino terminal region to 
interact with the extracellular region of an integral membrane protein that also 
contains a localization signal in its cytoplasmic domain for clathrin-mediated 
endocytosis. 
While GPI anchored proteins have many diverse functions, a definitive 
understanding of the physiological function of PrP is still unknown.  With the 
intent of understanding the function of PrP, two independent lines of PrP 
knockout mice were generated. The lines differed in the strategy used to disrupt 
Prnp gene expression: in Zurich PrP0/0 mice, a portion of exon 3 of the Prnp gene 
was replaced with a neomycin phosphotransferase (neo) gene (Bueler et al., 
1992) and in Edinburgh PrP-/- mice, a neo gene was inserted into exon 3 of the 
Prnp gene (Manson et al., 1994). In both lines of mice, there was a lack of overt 
disturbances in development or behavior (Bueler et al., 1992; Manson et al., 
1994). Though PrP KO mice did not obviously suggest a function for PrP, they 
did provide definitive evidence that expression of PrP was necessary for 
productive infection with transmissible spongiform encephalopathies (Bueler et 
al., 1993; Sailer et al., 1994). 
 Further examination of PrP knockout mice revealed several subtle 
abnormalities suggestive of varied physiological functions (Table 1). However, 
many of the functional studies compared PrP KO mice to PrP expressing mice 
with different genetic backgrounds. Both Zurich PrP0/0 and Edinburgh PrP-/- mice 
were constructed using a sub-strain of 129 embryonic stem cells. However, to 
maintain the PrP knockout phenotype, many subsequent lines were crossed to 
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different strains of mice resulting in a mixed background. Thus, in several 
studies, the possibility exists that the phenotype is a result of other genes whose 
alleles differ between the knockout and wild-type mice compared. The only 
studies to compare mice of the same genetic background (Edinburgh PrP-/- 
versus 129/Ola mice) demonstrated PrP KO mice to have an abnormal quantity 
and morphology of mitochondria (Miele et al., 2002), altered regulation of amyloid 
beta production in the brain (Parkin et al., 2007), altered oxidative homeostasis in 
the brain (Wong et al., 2001) and an inability to induce long term potentiation 
(LTP) in the hippocampus (Manson et al., 1995). 
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Phenotype of PrP KO 
mice1 
Implied Function 
of PrP 
Background Strains of 
Mice Compared 2,3 Citation 
Did not have LTP deficits 
when exposed to amyloid-β 
oligomers 
Amyloid-β oligomer 
receptor 
PrP-/- bc C57BL.6 vs. C57 
BL/6 
PrP0/0 hybrid vs. C57BL6 
“hybrid” 
Lauren et al., 
2009 
Balducci et 
al., 2010 4 
Chronic demylenating 
polyneuropathy 5 Myelin maintenance PrP
0/0 bc Balb/c vs. Balb/c Bremer et al.,  
Increased susceptibility to 
kainate induced seizures 
Altered expression of 
glutamate and GABA 
receptor subunits 
Maintaining neuronal 
homeostasis 
PrP0/0 bc C57BL/6 vs. 
C57BL/6 
Rangel et al., 
2009 
Inefficient iron transport. 
Decreased iron content in    
red blood cells 
Iron uptake and 
transport PrP
0/0 bc FVB vs. FVB Singh et al., 2009 
Increased lung colonization of 
immortalized PrP0/0 
mesenchymal embryonic 
cells 
Control of metastasis 
formation 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
Muras et al., 
2009 
Reduced induction of T-
helper cell cytokines 
Poor control of autoimmune 
and infectious diseases 
Late T-cell activation 
antigen 
 
PrP0/0 bc FVB/N vs. FVB/N Ingram et al., 2009 
Reduced olfactory detection 5 
Reduced paired pulse 
plasticity at dendrodendritic 
synapses 5 
Influences 
processing of 
sensory information 
by the olfactory 
system 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
PrP-/- vs. 129/Ola 
Le Pichon et 
al., 2009 
Increased anxiety and poor 
performance in social 
recognition asks following 
brain injury influencing 
cortical development 
Aids in recovery 
following brain injury 
Influences cortical 
development relating 
to short term memory 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
 
Xikota et al., 
2008 
Slower rate of astrocyte 
maturation 
Reduced neuritogenesis 
Receptor for stress 
inducible protein 
Mediates astrocyte 
development 
Modulates neuron-
glia crosstalk 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
PrP-/- bc C57BL/10 vs., 
Prnpwt/wt 
Arantes et al., 
2009 
Caetano et 
al., 2008 
Lima et al., 
2007 
Delayed feedback inhibition 
of hypothalamic-pituitary-
adrenal (HPA) axis following 
acute stress 
Regulation of HPA 
axis PrP
-/- vs. 129/Ola 
Sanchez-
Alavez et al., 
2008 
Abnormal functioning and 
lack of LTP formation in 
cerebellar granule cells 
Poor performance in motor 
control tasks 
Granule cell 
development 
PrP0/0 mixed vs. F2 
(129S1/SvImJ X C57BL/6J) 
 
Prestori et al., 
2008 
Decreased defense 
responses when confronted 
with coral snakes 
Modulation of innate 
fear and panic 
related behaviors 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
Lobao-Soares 
et al., 2008 
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Phenotype of PrP KO 
mice1 
Implied Function 
of PrP 
Background Strains of 
Mice Compared 2,3 Citation 
Higher activity of neutral and 
acid sphingomyelinase 
Regulation of 
sphingolipid 
associated signaling 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
Schmalzbauer 
et al., 2008 
Increased and prolonged 
NMDA evoked currents in 
hippocampal neurons 
Increased susceptibility to 
NMDA mediated neuronal 
death 
Inhibitor of NR2D 
subunit of NMDA 
receptor 
Littermates of PrP0/0 X 129 
or FVB) 
Khosravani et 
al., 2008 
Decreased infiltration of 
inflammatory cells and 
activated microglia following 
encephalomyocarditis virus 
infection 
Increased neuronal apoptosis 
Role in induction of 
inflammation and 
inhibitor of apoptosis 
PrP0/0 mixed vs. F1 (Prnp0/+ 
X Prnp0/+) 
Nasu-
Nishimura et 
al., 2008 
Weaker 
afterhyperpolarizations in 
cererbellar and hippocampal 
neurons due to stronger 
calcium buffering and 
extrusion rates 
Role in neuronal 
calcium homeostasis PrP
0/0 bc FVB/N vs. FVB/N Powell et al., 2008 
Increased mitochondrial 
respiration and free radical 
production 
Defects in mitochondrial 
morphology 
Altered superoxide dismutase 
activities 
Protection against 
oxidative stress PrP
-/- vs. 129/Ola 
Paterson et 
al., 2008 
Lobao-Soares 
et al., 20054 
Altered dorsal root ganglion 
axonal growth (substrate 
dependent) 
Interacts with 
vitronectin 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
PrP-/- bc C57BL/10 vs., 
Prnpwt/wt 
Hajj et al., 
2007 
Resistant to thermal and 
visceral inflammatory 
nociception 
Role in nocicpetive 
transmission 
mediated by 
inflammation 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
 
Meotti et al., 
2007 
Decreased [Ca2+] I levels 
Decreased neuronal viability 
to H2O2 
H2O2 sensor 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
 
Krebs et al., 
2007 
Higher percentage of CD8+ 
spleen dendritic cells 
Influences 
development of CD8- 
dendritic cells 
PrP0/0 bc C57BL/6 vs. 
C57Bl/6 
Martínez del 
Hoyo G, 2006 
Decreased Ca2+ influx via L-
type voltage gated Ca2+ 
channels 
Ca2+ homeostasis  Littermates of C57Bl6 x 129Sv Prnp+/- mice  
Fuhrmann et 
al., 2006 
Reduced allogenic T Cell 
response 
Role in 
immunological 
synapse between 
dendritic cells and T 
cells 
PrP0/0 bc C57BL/6 vs. 
C57Bl/6 
Ballerini et al., 
2006 
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Phenotype of PrP KO 
mice1 
Implied Function 
of PrP 
Background Strains of 
Mice Compared 2,3 Citation 
Increased infarct volume 
following transient or 
permanent ischemia 
Reduced Akt activation 
Enhanced caspase 3 
activation 
Anti-apoptotic 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
 
Weise et al., 
2006 
Delay in neural differentiation 
Role in neurogenesis 
and adult neural 
development 
PrP-/- bc C57BL.6 vs. C57 
BL/6 
Steele et al., 
2006 
Impaired self renewal of 
hematopoietic stem cells 
Supports self renewal 
of hematopoietic 
stem cells 
PrP-/- bc four or six times to 
C57 BL/6J CD45.2 vs. 
CD45.2 C57BL/6 
Zhang et al., 
2006 
Arrested NCAM dependent 
neurite outgrowth 
Nervous system 
development using 
NCAM as a signaling 
receptor 
PrP0/0 bc C57BL/6 vs. 
C57Bl/6 
Santuccione 
et al., 2005 
Impaired hippocampal 
dependent spatial learning 
Impaired LTP in dentate gyrus 
Regulator of 
glutamatergic 
signaling 
PrP-/- bc two times to 
C57BL.6 vs. C57 BL/6 
PrP-/- vs. 129/Ola 
Criado et al., 
20055 
Reduced copper content in 
synaptosomes 
Regulates copper 
concentrations in 
synaptosomes 
PrP0/0 hybrid vs. C57BL6 
and 129 “hybrid” 
Giese et al., 
2005 
Increased male susceptibility 
to ischemia 
Neuroprotection 
against ischemia PrP
0/0 hybrid vs. C57BL/6 
Sakurai-
Yamashita et 
al., 2005 
Decreased anxiety and 
locomotion in response to 
acute stress 
Modulation of anxiety 
and muscle activity in 
response to stress 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
 
Nico et al., 
2005 
Increased infarct size (200% 
after ischemia, increased 
Erk1/2, STAT I and caspase 3 
Neuroprotective, anti-
apoptotic 
PrP0/0 mixed vs. F1 (129/Sv 
X C57BL/6J) 
Spudich et al., 
2005 
 
 
1 Phenotype of PrP KO mice or primary cells harvested from PrP KO mice 
2 PrP 0/0 = Zurich PrP KO mice on a mixed background. PrP -/- = Edinburgh PrP KO mice on a 129/Ola 
background 
3 bc = backcross to the wild-type strain (as indicated) for at least eight generations 
4 Disputed results or conclusions of the study 
5 Phenotypic rescue in PrP expressing transgenic lines of mice 
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 A number of studies, albeit using mice of different backgrounds, have also 
reported synaptic abnormalities relating to L-glutamatergic neurotransmission. 
PrP KO mice suffer from deficits in hippocampal spatial memory (Criado et al., 
2005), have abnormal responses to NMDA receptor antagonist  MK-801(Coitinho 
et al., 2002)  and exhibit reduced excitatory post-synaptic potentials (Carleton et 
al., 2001) and afterhyperpolarization potentials (Mallucci et al., 2002). Decreased 
levels of LTP in PrP KO mice has been rescued by expression either of human 
PrP (Whittington et al., 1995; Asante et al., 2004) or by neuronal expression of 
mouse PrP (Criado et al., 2005). Primary neurons cultured from PrP KO mice 
exhibit increased NMDA receptor activation and an increased vulnerability to 
NMDA mediated excitotoxicity (Khosravani et al., 2008). Collectively, these 
observations suggest that PrP KO mice suffer from deficits in neurotransmission, 
consistent with attenuated glutamate signaling, which could result from excessive 
clearance of L-glutamate from the synaptic space. 
 
 
1.2 The Glutamatergic System 
 L-glutamate is the primary excitatory neurotransmitter in the mammalian 
nervous system, mediating neuronal communication that includes fast synaptic 
transmission and higher order processing necessary for development and 
learning and memory. L-glutamate is sequestered intracellularly maintaining an 
intracellular-extracellular concentration gradient of several million-fold (Zerangue 
and Kavanaugh, 1996; Herman and Jahr, 2007). Thus, preserving homeostatic 
levels of L-glutamate is important in maintaining specificity of signaling and 
appropriate receptor activation. 
 The highest concentration of L-glutamate in the CNS is found in nerve 
terminals (Ottersen et al., 1992) . Here, L-glutamate is packaged into synaptic 
vesicles by proton-dependent vesicular transporter, V-GLUT. Once an action 
potential reaches the nerve terminal, vesicles loaded with L-glutamate fuse with 
the plasma membrane and release their contents extracellularly. In the synaptic 
space, L-glutamate can activate G-protein coupled metabotropic L-glutamate 
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receptors and ionotropic L-glutamate receptors. Diffusion of L-glutamate also 
permits activation of receptors extrasynaptically. 
 Metabotropic L-glutamate receptors are G-protein coupled receptors 
whose activation play a modulatory role by regulating the production of 
intracellular messengers and consequently activating or inhibiting second 
messenger systems. The receptors belong to Class C G-protein coupled 
receptors, characterized by 7 transmembrane helices connected by 3 
intracellular and 3 extracellular loops. To date, there have been 8 metabotropic 
glutamate receptors cloned that are divided into 3 groups. Group I includes 
mGlu1 and mGlu5 that are localized post-synaptically on neurons and who are 
coupled to phosplipase C. Group II includes mGlu2 and mGlu3, found both pre- 
and post-synaptically and are negatively coupled to adenylyl cyclase. Group III 
includes mGlu4, mGlu6, mGlu7 and mGlu8 that are localized pre-synaptically. 
The synaptic location of these receptors allows them to modulate both 
neurotransmitter release and regulation of fast acting ionotropic L-glutamate 
receptors.    
 Fast-acting ionotropic L-glutamate receptors are L-glutamate gated ion 
channels that permit an influx of sodium and/or calcium from the extracellular 
environment to the inside of the cell. Binding of L-glutamate to low affinity AMPA 
or Kainate receptors (who also preferentially bind AMPA and kainate, 
respectively) causes an influx of sodium, which serves to depolarize the cell. In 
contrast, the high affinity NMDA receptor acts as a coincidence detector, 
requiring glycine and L-glutamate binding, as well as previous depolarization of 
the membrane in order to permit the entrance of sodium and calcium into the cell. 
Compared to AMPA and kainate receptors, NMDA receptors have slow 
deactivation times and are critical in mediating higher order processing. 
Several distinct subtype compositions have been identified differing in 
their sensitivities to pharmacological agents, their channel opening times, their 
distribution in the brain and their relative concentrations during development.  
Most NMDA receptors are heteromeric molecules consisting of two obligatory 
NR1 subunits and two NR2 subunits. Four isoforms of the NR2 subunit have 
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been identified, NR2A, NR2B, NR2C and NR2D. These isoforms are distinct in 
determining characteristics of the NMDA receptor, which influence channel 
kinetics. The type of NR2 subunit present determines deactivation times of the 
receptor in response to L-glutamate. The deactivation times span a 50-fold range 
with NR2A subunits deactivating fastest and NR2D subunits slowest (NR2A > 
NR2C = NR2B >> NR2D). NMDA receptor subunit composition and subsequent 
receptor deactivation kinetics reflect the nature of the synapse in which they are 
expressed. NR2A containing receptors are present at most mature synapses 
while NR2B containing receptors are expressed predominantly during 
development. The changes in the molecular makeup of NMDARs are part of 
what defines the “critical period” during development in which neuronal circuits 
are fine tuned (Cull-Candy and Leszkiewicz, 2004).  
 L-glutamate is the major excitatory neurotransmitter in the CNS and as 
such, extracellular levels of L-glutamate must be tightly controlled to maintain 
specificity of signaling. Depending on the location of the synapse, L-glutamate 
signaling has various functions throughout the CNS such as mediating 
experience dependent synaptic plasticity through the phenomena of long-term 
potentiation (LTP) and long-term depression (LTD), development and fine-tuning 
of excitatory synapses, the perception of pain and modulation of signaling by 
other neurotransmitters such as dopamine. The concentration of L-glutamate in 
the extracellular space and the amount of time it remains in the space 
determines the number of L-glutamate receptors activated. Therefore, keeping 
extracellular concentrations of L-glutamate low allows for a high signal-to-noise 
ratio in synaptic and extrasynaptic transmission (Danbolt 2001).  
Furthermore, keeping the extracellular concentration of L-glutamate low 
prevents neuronal death. Excessive activation of L-glutamate receptors and 
prolonged excitatory synaptic transmission can lead to neuronal death through 
excitotoxicity (Olney 1996). L-glutamate mediated excitotoxicity is mediated by a 
sustained activation of L-glutamate receptors. Because of its high permeability to 
calcium, the NMDA receptor in particular mediates the majority of excitotoxic 
insult although AMPA and Kainate receptors play a role in sustained 
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depolarization of neurons (Salinska et al., 2005; Waxman and Lynch 2005). The 
molecular events leading to neuronal death are unclear although altered calcium 
homeostasis plays a distinctive role in dysregulation of signal transduction 
pathways, activation of calcium dependent calpains (Wu et al., 2004), and 
activation of metabolic pathways that generate free radicals (Salinska et al., 
2005). Neuronal death follows excitotoxicity and therapeutic strategies aimed 
against excitotoxcity are hoped to delay pathogenesis of many neurodegerative 
diseases.  
Thus, maintaining basal concentrations of L-glutamate is critical in 
maintaining signal specificity and preventing neuronal death. Levels of L-
glutamate following vesicular release are believed to reach millimolar levels 
during excitatory transmission (Clements 1992) but must be rapidly cleared to 
markedly lower (0.1-1µM) homeostatic levels (Herman and Jahr 2007). 
Extracellular L-glutamate concentrations are regulated by the activity of 
excitatory amino acid transporters present on neurons and astrocytes. 
 
1.3 Excitatory Amino Acid Transporters 
  Unlike other neurotransmitters, such as acetylcholine whose extracellular 
concentrations are controlled by enzymatic degradation, rapid termination of L-
glutamate signaling is achieved by cellular uptake. The majority of L-glutamate 
transport is mediated by high affinity, Na+ dependent excitatory amino acid 
transporters (EAATs). To date, five EAAT subtypes with high affinity for L-
glutamate have been identified.  EAAT1 (GLAST) and EAAT2 (GLT-1) are 
primarily glial transporters responsible for the bulk of L-glutamate clearance. 
EAAT3 (EAAC), EAAT4 and EAAT5 are expressed by neurons.   
Levels of transporter subtypes are regionally, developmentally and functionally 
specific.  
 Characterization of the EAATs was aided by molecular pharmacology, 
used to both distinguish between subtypes and understand the transport 
process. Experiments aimed at understanding basic amino acid substrate 
selectivity identified D-aspartate as an inhibitor of L-glutamate uptake and 
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excellent alternate substrate with a Km in glial cultures of 60-80µM compared to 
L-glutamate whose Km is 30-90µM (reviewed in Bridges et al., 1999). One of the 
earliest competitive inhibitors characterized, effective at all five EAATs and a 
substrate of EAAT1-4, was B-threo-hydroxyaspartate (ß-THA). Subsequently, ß-
THA has been used as a backbone for the development of other EAAT inhibitors 
incuding ß-threo-benzyloxyaspartate (TBOA), a non-substrate pan-EAAT 
inhibitor with Ki values in the 1-10µM range.  
To date, the majority of inhibitors exhibiting a high degree of selectivity for 
one transporter subtype over the others are limited to EAAT2. Potent inhibitors of 
EAAT2 include the classic inhibitor dihydrokainate (DHK, Ki = 23µM) and, more 
recently, WAY213613 (IC50 = 85nM) (Bridges et al., 1999; Dunlop et al., 2005). 
Alternate substrates at EAAT1, 4-MG and L-serine-O-sulfate can be used to 
distinguish EAAT 1 from EAAT2 activity. Recently, a selective EAAT1 inhibitor, 
UCPH 101, has been developed (Jensen et al., 2009). The usage of 
pharmacology, either through subtype selective inhibitors or through subtype 
specific alternate substrates, has allowed understanding the delineation of 
subtype-specific roles in the transport of L-glutamate. 
Glial transporters, EAAT1 and EAAT2 are expressed throughout the 
mature CNS and are responsible for the majority of L-glutamate clearance. 
However, there is developmental and regional enrichment of one subtype over 
the other. During development, EAAT1 is the dominant transporter expressed 
and functional though protein levels of both transporters increase dramatically 
during synaptogenesis (Shibata et al., 1996; Sutherland et al., 1996). In the adult 
however, EAAT1 expression and function dominates in Bergmann glia of the 
cerebellum. In other regions of the brain, EAAT2 is the major glutamate 
transporter functional though EAAT1 expression remains high (Danbolt, 2001). 
Whether the same astrocyte expresses both EAAT1 and EAAT2 is controversial; 
immunogold labeling demonstrated co-expression (Haugeto et al., 1996) while 
analysis of promoter activity demonstrated a non-overlapping pattern of 
expression (Regan et al., 2007). The importance of the relative stoichiometry of 
one subtype over the other in a single astrocyte or region is unknown. EAAT2 
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knockout mice do suffer from lethal spontaneous seizures (Tanaka et al., 1997). 
However, levels of neuronal death following selective pharmacological 
inactivation of EAAT2 in adult mice did not mirror that when all glutamate 
transporters were rendered inactive (Selkirk et al., 2005), suggesting that 
following stress, EAAT1 can rapidly be mobilized for dominant function.  
In contrast to glial L-glutamate transporters, neuronal transporters are 
considered to make a minor contribution to overall L-glutamate clearance. 
EAAT3 expression is highest in the hippocampus, cerebellum, basal ganglia, 
forebrain and spinal cord. EAAT4 expression is highest on Purkinje neurons in 
the cerebellum and EAAT5 expression is limited to the retina. EAAT3 and EAAT4 
are expressed postsynaptically and are though to provide L-glutamate as a 
precursor for GABA synthesis (Sepkuty et al., 2002).   
 
Figure 1.2 The Glutamatergic Synapse.  
Following an action potential in the presynaptic neuron, L-glutamate vesicles fuse with the plasma 
membrane and release L-glutamate into the synaptic cleft. L-glutamate can bind to and activate 
NMDA, AMPA, Kainate and metabotropic L-glutamate receptors causing fast or long-lasting 
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changes in the activated neuron. The L-glutamate signal is terminated by transport of L-glutamate 
into astrocytes by EAAT1 and EAAT2. L-glutamate is then rapidly synthesized into glutamine 
(Gln) by glutamine synthetase. L-Glutamate is also transported by EAAT3 and Xct. EAAT 3 is 
localized to neurons and provides L- glutamate for GABA synthesis. System Xct, localized to 
astrocytes, exchanges glutamate for cysteine, which is subsequently used for gluthathione 
synthesis. PrP is expressed on astrocytes and neurons in the synapse. 
The EAATs are defined as symporters, transporting the substrate by co-
transport and counter-transport of ions (Bunch et al., 2009). The overall goal of 
transport is to accumulate L-glutamate intracellularly against its concentration 
gradient. This is powered by the co-transport of 3 Na+ ions and one H+ ion. 
Following release of co-transported L-glutamate and ions, one K+ ion is counter-
transported and released to the extracellular space (Zerangue and Kavanaugh, 
1996). The EAATs also conduct a thermodynamically uncoupled Cl- flux, thereby 
acting as a Cl- channel (Wadiche et al., 1995a).  
 The transport cycle occurs by an alternating access mechanism 
(Kavanaugh, 1998; Yernool et al., 2004) or cow chute mechanism (personal 
communication, Terri Mavencamp) in which two major conformations of the 
EAATs are employed. The first conformation is an outward conformation where 
the substrate-binding site faces the synaptic space. The second conformation is 
inward, allowing the substrate-binding site to be accessible to the cytoplasm of 
the cell. The full cycle of transport begins with binding of the co-transported ions 
(3 Na+, 1 H+) and substrate to the transporter in the outward conformation. This 
leads to translocation of the transporter resulting in an inwards conformation. The 
co-transported ions and substrate are released and intracellular K+ binds. 
Consequently, the substrate binding site reorients to the outside (Tzingounis and 
Wadiche, 2007). Possibly due to the steps required sequester L-glutamate 
intracellulary, the full cycle is relatively slow, estimated to be between 60-80ms 
(Wadiche et al., 1995b). Reconciling the slow transport cycle with the mM 
amounts of L-glutamate present in the synaptic cleft during vesicular release 
suggest that the EAATs initially function as L-glutamate buffers, terminating 
excitatory signaling by trapping L-glutamate (Diamond et al., 1997). 
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 Much of the structure of the EAATs has been inferred following the 
elucidation of the crystal structure of a bacterial orthologue of the EAATs, a 
sodium-dependent Asp transporter from Pyrococcus horikoshii, GltPh  (Yernool et 
al., 2004). The membrane transporter is composed of a bowl shaped homomer 
with three independent subunits. Each subunit of the trimer is capable of a 
transport cycle. The monomer contains an intercellular N and C termini, eight 
transmembrane (TM) regions and two hairpin loops. The glutamate binding site is 
at the bottom of the bowl, between the 2 hairpin loops, which are hypothesized to 
act as gates to the binding site (Boudker et al., 2007). The EAATs are 
glycosylated in the hydrophilic loop between TM 3 and TM4 although the number 
of glycosylations in the region differ among the EAAT subtypes (Seal and Amara, 
1999). 
 The overall purpose of the EAATs is to maintain homeostatic levels of L-
glutamate. Too much L-glutamate can lead to neuronal death through initiation of 
excitotoxic cascades. The impact of glial protection from L-glutamate mediated 
excitotoxicity through EAAT activity has been demonstrated in primary cultures 
altering glia/neuron ratios and by pharmacological blockade of the EAATs 
(Rosenberg and Aizenman, 1989; Robinson et al., 1993; Rothstein et al., 1996). 
Several neurodegenerative diseases have implicated low EAAT activity as 
contributing to pathology, including amyotrophic lateral sclerosis (ALS) (Rothstein 
et al., 1992), HIV-associated dementia (Sardar et al., 1999), and Alzheimer’s 
Disease (Masliah et al., 1996). Thus, increasing activity has been a therapeutic 
target. In a mouse model of ALS, increased EAAT expression through 
administration of β-lactam antibiotics delayed neuronal loss (Rothstein et al., 
2005). However, high EAAT activity can also decrease the amount of synaptic L-
glutamate necessary for proper L-glutamatergic neurotransmission. Elevated L-
glutamate transport has led to decreased LTP in the hippocampus (Filosa et al., 
2009) and impaired hippocampal dependent learning (Carmona et al., 2009). 
Hyperactive EAAT activity might contribute to reduced L-glutamatergic signaling 
observed in schizophrenia (Miyamoto et al., 2005). Thus, the EAATs play a 
powerful role in carefully regulating activation of L-glutamate receptors, ensuring 
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enough L-glutamate can be present for signaling without having too much to 
initiate excitotoxic pathways. Dysfunction in EAAT activity may be one of the 
causes of disease in Transmissible Spongiform Encephalopathies. 
 17 
 
References 
 
Aguzzi A, Baumann F, Bremer J (2008) The prion's elusive reason for being. 
Annu Rev Neurosci 31:439-477. 
Arantes C, Nomizo R, Lopes MH, Hajj GN, Lima FR, Martins VR (2009) Prion 
protein and its ligand stress inducible protein 1 regulate astrocyte 
development. Glia 57:1439-1449. 
Asante EA, Li YG, Gowland I, Jefferys JG, Collinge J (2004) Pathogenic human 
prion protein rescues PrP null phenotype in transgenic mice. Neurosci Lett 
360:33-36. 
Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, 
Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, 
Forloni G (2010) Synthetic amyloid-beta oligomers impair long-term 
memory independently of cellular prion protein. Proc Natl Acad Sci U S A 
107:2295-2300. 
Ballerini C, Gourdain P, Bachy V, Blanchard N, Levavasseur E, Gregoire S, 
Fontes P, Aucouturier P, Hivroz C, Carnaud C (2006) Functional 
implication of cellular prion protein in antigen-driven interactions between 
T cells and dendritic cells. J Immunol 176:7254-7262. 
Basler K, Oesch B, Scott M, Westaway D, Walchli M, Groth DF, McKinley MP, 
Prusiner SB, Weissmann C (1986) Scrapie and cellular PrP isoforms are 
encoded by the same chromosomal gene. Cell 46:417-428. 
Boudker O, Ryan RM, Yernool D, Shimamoto K, Gouaux E (2007) Coupling 
substrate and ion binding to extracellular gate of a sodium-dependent 
aspartate transporter. Nature 445:387-393. 
Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P, Steele AD, 
Toyka KV, Nave KA, Weis J, Aguzzi A Axonal prion protein is required for 
peripheral myelin maintenance. Nat Neurosci 13:310-318. 
Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C 
(1993) Mice devoid of PrP are resistant to scrapie. Cell 73:1339-1347. 
 18 
Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, Prusiner 
SB, Aguet M, Weissmann C (1992) Normal development and behaviour of 
mice lacking the neuronal cell-surface PrP protein. Nature 356:577-582. 
Bunch L, Erichsen MN, Jensen AA (2009) Excitatory amino acid transporters as 
potential drug targets. Expert Opin Ther Targets 13:719-731. 
Caetano FA, Lopes MH, Hajj GN, Machado CF, Pinto Arantes C, Magalhaes AC, 
Vieira Mde P, Americo TA, Massensini AR, Priola SA, Vorberg I, Gomez 
MV, Linden R, Prado VF, Martins VR, Prado MA (2008) Endocytosis of 
prion protein is required for ERK1/2 signaling induced by stress-inducible 
protein 1. J Neurosci 28:6691-6702. 
Carleton A, Tremblay P, Vincent JD, Lledo PM (2001) Dose-dependent, prion 
protein (PrP)-mediated facilitation of excitatory synaptic transmission in 
the mouse hippocampus. Pflugers Arch 442:223-229. 
Carmona MA, Murai KK, Wang L, Roberts AJ, Pasquale EB (2009) Glial ephrin-
A3 regulates hippocampal dendritic spine morphology and glutamate 
transport. Proc Natl Acad Sci U S A 106:12524-12529. 
Coitinho AS, Dietrich MO, Hoffmann A, Dall'Igna OP, Souza DO, Martins VR, 
Brentani RR, Izquierdo I, Lara DR (2002) Decreased hyperlocomotion 
induced by MK-801, but not amphetamine and caffeine in mice lacking 
cellular prion protein (PrP(C)). Brain Res Mol Brain Res 107:190-194. 
Criado JR, Sanchez-Alavez M, Conti B, Giacchino JL, Wills DN, Henriksen SJ, 
Race R, Manson JC, Chesebro B, Oldstone MB (2005) Mice devoid of 
prion protein have cognitive deficits that are rescued by reconstitution of 
PrP in neurons. Neurobiol Dis 19:255-265. 
Cull-Candy SG, Leszkiewicz DN (2004) Role of distinct NMDA receptor subtypes 
at central synapses. Sci STKE 2004:re16. 
Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65:1-105. 
Diamond JS, Jahr CE (1997) Transporters buffer synaptically released glutamate 
on a submillisecond time scale. J Neurosci 17:4672-4687. 
Filosa A, Paixao S, Honsek SD, Carmona MA, Becker L, Feddersen B, Gaitanos 
L, Rudhard Y, Schoepfer R, Klopstock T, Kullander K, Rose CR, Pasquale 
 19 
EB, Klein R (2009) Neuron-glia communication via EphA4/ephrin-A3 
modulates LTP through glial glutamate transport. Nat Neurosci 12:1285-
1292. 
Fuhrmann M, Bittner T, Mitteregger G, Haider N, Moosmang S, Kretzschmar H, 
Herms J (2006) Loss of the cellular prion protein affects the Ca2+ 
homeostasis in hippocampal CA1 neurons. J Neurochem 98:1876-1885. 
Gossert AD, Bonjour S, Lysek DA, Fiorito F, Wuthrich K (2005) Prion protein 
NMR structures of elk and of mouse/elk hybrids. Proc Natl Acad Sci U S A 
102:646-650. 
Hajj GN, Lopes MH, Mercadante AF, Veiga SS, da Silveira RB, Santos TG, 
Ribeiro KC, Juliano MA, Jacchieri SG, Zanata SM, Martins VR (2007) 
Cellular prion protein interaction with vitronectin supports axonal growth 
and is compensated by integrins. J Cell Sci 120:1915-1926. 
Haugeto O, Ullensvang K, Levy LM, Chaudhry FA, Honore T, Nielsen M, Lehre 
KP, Danbolt NC (1996) Brain glutamate transporter proteins form 
homomultimers. J Biol Chem 271:27715-27722. 
Ingram RJ, Isaacs JD, Kaur G, Lowther DE, Reynolds CJ, Boyton RJ, Collinge J, 
Jackson GS, Altmann DM (2009) A role of cellular prion protein in 
programming T-cell cytokine responses in disease. FASEB J 23:1672-
1684. 
Kavanaugh MP (1998) Neurotransmitter transport: models in flux. Proc Natl Acad 
Sci U S A 95:12737-12738. 
Khosravani H, Zhang Y, Tsutsui S, Hameed S, Altier C, Hamid J, Chen L, 
Villemaire M, Ali Z, Jirik FR, Zamponi GW (2008) Prion protein attenuates 
excitotoxicity by inhibiting NMDA receptors. J Cell Biol 181:551-565. 
Krebs B, Wiebelitz A, Balitzki-Korte B, Vassallo N, Paluch S, Mitteregger G, 
Onodera T, Kretzschmar HA, Herms J (2007) Cellular prion protein 
modulates the intracellular calcium response to hydrogen peroxide. J 
Neurochem 100:358-367. 
 20 
Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular 
prion protein mediates impairment of synaptic plasticity by amyloid-beta 
oligomers. Nature 457:1128-1132. 
Le Pichon CE, Valley MT, Polymenidou M, Chesler AT, Sagdullaev BT, Aguzzi A, 
Firestein S (2009) Olfactory behavior and physiology are disrupted in prion 
protein knockout mice. Nat Neurosci 12:60-69. 
Lima FR, Arantes CP, Muras AG, Nomizo R, Brentani RR, Martins VR (2007) 
Cellular prion protein expression in astrocytes modulates neuronal survival 
and differentiation. J Neurochem 103:2164-2176. 
Lobao-Soares B, Walz R, Prediger RD, Freitas RL, Calvo F, Bianchin MM, Leite 
JP, Landemberger MC, Coimbra NC (2008) Cellular prion protein 
modulates defensive attention and innate fear-induced behaviour evoked 
in transgenic mice submitted to an agonistic encounter with the tropical 
coral snake Oxyrhopus guibei. Behav Brain Res 194:129-137. 
Lobao-Soares B, Bianchin MM, Linhares MN, Carqueja CL, Tasca CI, Souza M, 
Marques W, Jr., Brentani R, Martins VR, Sakamoto AC, Carlotti CG, Jr., 
Walz R (2005) Normal brain mitochondrial respiration in adult mice lacking 
cellular prion protein. Neurosci Lett 375:203-206. 
Magalhaes AC, Silva JA, Lee KS, Martins VR, Prado VF, Ferguson SS, Gomez 
MV, Brentani RR, Prado MA (2002) Endocytic intermediates involved with 
the intracellular trafficking of a fluorescent cellular prion protein. J Biol 
Chem 277:33311-33318. 
Mallucci GR, Ratte S, Asante EA, Linehan J, Gowland I, Jefferys JG, Collinge J 
(2002) Post-natal knockout of prion protein alters hippocampal CA1 
properties, but does not result in neurodegeneration. Embo J 21:202-210. 
Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J (1994) 
129/Ola mice carrying a null mutation in PrP that abolishes mRNA 
production are developmentally normal. Mol Neurobiol 8:121-127. 
Manson JC, Hope J, Clarke AR, Johnston A, Black C, MacLeod N (1995) PrP 
gene dosage and long term potentiation. Neurodegeneration 4:113-114. 
 21 
Martínez del Hoyo G L-BM, Metharom P, Ardavín C, Aucouturier P. (2006) Prion 
protein expression by mouse dendritic cells is restricted to the 
nonplasmacytoid subsets and correlates with the maturation state. J 
Immunol 177:6137-6142. 
Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L (1996) Deficient 
glutamate transport is associated with neurodegeneration in Alzheimer's 
disease. Ann Neurol 40:759-766. 
Meotti FC, Carqueja CL, Gadotti Vde M, Tasca CI, Walz R, Santos AR (2007) 
Involvement of cellular prion protein in the nociceptive response in mice. 
Brain Res 1151:84-90. 
Miele G, Jeffrey M, Turnbull D, Manson J, Clinton M (2002) Ablation of cellular 
prion protein expression affects mitochondrial numbers and morphology. 
Biochem Biophys Res Commun 291:372-377. 
Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for 
schizophrenia: a critical review of pharmacology and mechanisms of 
action of antipsychotic drugs. Mol Psychiatry 10:79-104. 
Muras AG, Hajj GN, Ribeiro KB, Nomizo R, Nonogaki S, Chammas R, Martins 
VR (2009) Prion protein ablation increases cellular aggregation and 
embolization contributing to mechanisms of metastasis. Int J Cancer 
125:1523-1531. 
Nasu-Nishimura Y, Taniuchi Y, Nishimura T, Sakudo A, Nakajima K, Ano Y, 
Sugiura K, Sakaguchi S, Itohara S, Onodera T (2008) Cellular prion 
protein prevents brain damage after encephalomyocarditis virus infection 
in mice. Arch Virol 153:1007-1012. 
Ottersen OP, Zhang N, Walberg F (1992) Metabolic compartmentation of 
glutamate and glutamine: morphological evidence obtained by quantitative 
immunocytochemistry in rat cerebellum. Neuroscience 46:519-534. 
Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, Baybutt 
HN, Turner AJ, Hooper NM (2007) Cellular prion protein regulates beta-
secretase cleavage of the Alzheimer's amyloid precursor protein. Proc 
Natl Acad Sci U S A 104:11062-11067. 
 22 
Paterson AW, Curtis JC, Macleod NK (2008) Complex I specific increase in 
superoxide formation and respiration rate by PrP-null mouse brain 
mitochondria. J Neurochem 105:177-191. 
Peters PJ, Mironov A, Jr., Peretz D, van Donselaar E, Leclerc E, Erpel S, 
DeArmond SJ, Burton DR, Williamson RA, Vey M, Prusiner SB (2003) 
Trafficking of prion proteins through a caveolae-mediated endosomal 
pathway. J Cell Biol 162:703-717. 
Powell AD, Toescu EC, Collinge J, Jefferys JG (2008) Alterations in Ca2+-
buffering in prion-null mice: association with reduced 
afterhyperpolarizations in CA1 hippocampal neurons. J Neurosci 28:3877-
3886. 
Prestori F, Rossi P, Bearzatto B, Laine J, Necchi D, Diwakar S, Schiffmann SN, 
Axelrad H, D'Angelo E (2008) Altered neuron excitability and synaptic 
plasticity in the cerebellar granular layer of juvenile prion protein knock-out 
mice with impaired motor control. J Neurosci 28:7091-7103. 
Rangel A, Madronal N, Gruart i Masso A, Gavin R, Llorens F, Sumoy L, Torres 
JM, Delgado-Garcia JM, Del Rio JA (2009) Regulation of GABA(A) and 
glutamate receptor expression, synaptic facilitation and long-term 
potentiation in the hippocampus of prion mutant mice. PLoS One 4:e7592. 
Regan MR, Huang YH, Kim YS, Dykes-Hoberg MI, Jin L, Watkins AM, Bergles 
DE, Rothstein JD (2007) Variations in promoter activity reveal a differential 
expression and physiology of glutamate transporters by glia in the 
developing and mature CNS. J Neurosci 27:6607-6619. 
Robinson MB, Djali S, Buchhalter JR (1993) Inhibition of glutamate uptake with 
L-trans-pyrrolidine-2,4-dicarboxylate potentiates glutamate toxicity in 
primary hippocampal cultures. J Neurochem 61:2099-2103. 
Rosenberg PA, Aizenman E (1989) Hundred-fold increase in neuronal 
vulnerability to glutamate toxicity in astrocyte-poor cultures of rat cerebral 
cortex. Neurosci Lett 103:162-168. 
 23 
Rothstein JD, Martin LJ, Kuncl RW (1992) Decreased glutamate transport by the 
brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 
326:1464-1468. 
Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, 
Hediger MA, Wang Y, Schielke JP, Welty DF (1996) Knockout of 
glutamate transporters reveals a major role for astroglial transport in 
excitotoxicity and clearance of glutamate. Neuron 16:675-686. 
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, 
Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, 
Gupta P, Fisher PB (2005) Beta-lactam antibiotics offer neuroprotection by 
increasing glutamate transporter expression. Nature 433:73-77. 
Sailer A, Bueler H, Fischer M, Aguzzi A, Weissmann C (1994) No propagation of 
prions in mice devoid of PrP. Cell 77:967-968. 
Salinska E, Danysz W, Lazarewicz JW (2005) The role of excitotoxicity in 
neurodegeneration. Folia Neuropathol 43:322-339. 
Sanchez-Alavez M, Criado JR, Klein I, Moroncini G, Conti B (2008) 
Hypothalamic-pituitary-adrenal axis disregulation in PrPC-null mice. 
Neuroreport 19:1473-1477. 
Santuccione A, Sytnyk V, Leshchyns'ka I, Schachner M (2005) Prion protein 
recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to 
enhance neurite outgrowth. J Cell Biol 169:341-354. 
Sardar AM, Hutson PH, Reynolds GP (1999) Deficits of NMDA receptors and 
glutamate uptake sites in the frontal cortex in AIDS. Neuroreport 10:3513-
3515. 
Schmalzbauer R, Eigenbrod S, Winoto-Morbach S, Xiang W, Schutze S, Bertsch 
U, Kretzschmar HA (2008) Evidence for an association of prion protein 
and sphingolipid-mediated signaling. J Neurochem 106:1459-1470. 
Seal RP, Amara SG (1999) Excitatory amino acid transporters: a family in flux. 
Annu Rev Pharmacol Toxicol 39:431-456. 
Selkirk JV, Nottebaum LM, Vana AM, Verge GM, Mackay KB, Stiefel TH, Naeve 
GS, Pomeroy JE, Petroski RE, Moyer J, Dunlop J, Foster AC (2005) Role 
 24 
of the GLT-1 subtype of glutamate transporter in glutamate homeostasis: 
the GLT-1-preferring inhibitor WAY-855 produces marginal neurotoxicity in 
the rat hippocampus. Eur J Neurosci 21:3217-3228. 
Sepkuty JP, Cohen AS, Eccles C, Rafiq A, Behar K, Ganel R, Coulter DA, 
Rothstein JD (2002) A neuronal glutamate transporter contributes to 
neurotransmitter GABA synthesis and epilepsy. J Neurosci 22:6372-6379. 
Shibata T, Watanabe M, Tanaka K, Wada K, Inoue Y (1996) Dynamic changes in 
expression of glutamate transporter mRNAs in developing brain. 
Neuroreport 7:705-709. 
Shyng SL, Huber MT, Harris DA (1993) A prion protein cycles between the cell 
surface and an endocytic compartment in cultured neuroblastoma cells. J 
Biol Chem 268:15922-15928. 
Shyng SL, Heuser JE, Harris DA (1994) A glycolipid-anchored prion protein is 
endocytosed via clathrin-coated pits. J Cell Biol 125:1239-1250. 
Singh A, Kong Q, Luo X, Petersen RB, Meyerson H, Singh N (2009) Prion 
protein (PrP) knock-out mice show altered iron metabolism: a functional 
role for PrP in iron uptake and transport. PLoS One 4:e6115. 
Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD (2006) Prion protein 
(PrPc) positively regulates neural precursor proliferation during 
developmental and adult mammalian neurogenesis. Proc Natl Acad Sci U 
S A 103:3416-3421. 
Sutherland ML, Delaney TA, Noebels JL (1996) Glutamate transporter mRNA 
expression in proliferative zones of the developing and adult murine CNS. 
J Neurosci 16:2191-2207. 
Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama 
H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, 
Takimoto M, Wada K (1997) Epilepsy and exacerbation of brain injury in 
mice lacking the glutamate transporter GLT-1. Science 276:1699-1702. 
Tzingounis AV, Wadiche JI (2007) Glutamate transporters: confining runaway 
excitation by shaping synaptic transmission. Nat Rev Neurosci 8:935-947. 
 25 
Wadiche JI, Amara SG, Kavanaugh MP (1995a) Ion fluxes associated with 
excitatory amino acid transport. Neuron 15:721-728. 
Wadiche JI, Arriza JL, Amara SG, Kavanaugh MP (1995b) Kinetics of a human 
glutamate transporter. Neuron 14:1019-1027. 
Waxman EA, Lynch DR (2005) N-methyl-D-aspartate receptor subtypes: multiple 
roles in excitotoxicity and neurological disease. Neuroscientist 11:37-49. 
Weise J, Sandau R, Schwarting S, Crome O, Wrede A, Schulz-Schaeffer W, Zerr 
I, Bahr M (2006) Deletion of cellular prion protein results in reduced Akt 
activation, enhanced postischemic caspase-3 activation, and exacerbation 
of ischemic brain injury. Stroke 37:1296-1300. 
Whittington MA, Sidle KC, Gowland I, Meads J, Hill AF, Palmer MS, Jefferys JG, 
Collinge J (1995) Rescue of neurophysiological phenotype seen in PrP 
null mice by transgene encoding human prion protein. Nat Genet 9:197-
201. 
Wong BS, Liu T, Li R, Pan T, Petersen RB, Smith MA, Gambetti P, Perry G, 
Manson JC, Brown DR, Sy MS (2001) Increased levels of oxidative stress 
markers detected in the brains of mice devoid of prion protein. J 
Neurochem 76:565-572. 
Wu HY, Tomizawa K, Oda Y, Wei FY, Lu YF, Matsushita M, Li ST, Moriwaki A, 
Matsui H (2004) Critical role of calpain-mediated cleavage of calcineurin in 
excitotoxic neurodegeneration. J Biol Chem 279:4929-4940. 
Xikota JC, Rial D, Ruthes D, Pereira R, Figueiredo CP, Prediger RD, Walz R 
(2008) Mild cognitive deficits associated to neocortical microgyria in mice 
with genetic deletion of cellular prion protein. Brain Res 1241:148-156. 
Yernool D, Boudker O, Jin Y, Gouaux E (2004) Structure of a glutamate 
transporter homologue from Pyrococcus horikoshii. Nature 431:811-818. 
Zerangue N, Kavanaugh MP (1996) Flux coupling in a neuronal glutamate 
transporter. Nature 383:634-637. 
Zhang CC, Steele AD, Lindquist S, Lodish HF (2006) Prion protein is expressed 
on long-term repopulating hematopoietic stem cells and is important for 
their self-renewal. Proc Natl Acad Sci U S A 103:2184-2189. 
 26 
 
 
 
 27 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
 
STUDY OF INFLUENCE OF PRION PROTEIN EXPRESSION ON FUNCTION 
OF EXCITATORY AMINO ACID TRANSPORTERS IN MOUSE PRIMARY 
ASTROCYTES 
By 
Melissa S. Pathmajeyan1, 2, 3, Sarjubhai A. Patel2, Todd Seib2, James F. Striebel1, 
Richard J. Bridges2, and Bruce Chesebro1* 
 
1 Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, NIAID, 
NIH, Hamilton, Montana 59840; 2 Center for Structural and Functional 
Neuroscience, University of Montana, Missoula, Montana 59802; 3 Department of 
Biology, University of Montana, Missoula, Montana 59802 
 28 
 
Abstract  
Prion protein (PrP) is expressed on a wide variety of cells and plays an important 
role in the pathogenesis of transmissible spongiform encephalopathies. However, 
its normal function remains unclear. Mice that do not express PrP exhibit deficits 
in spatial memory and abnormalities in excitatory neurotransmission suggestive 
that PrP may function in the glutamatergic synapse. Here we show that transport 
of D-aspartate, a non-metabolized L-glutamate analog, through excitatory amino 
acid transporters (EAATs) was faster in astrocytes from PrP knockout (PrP KO) 
mice than in astrocytes from C57BL/10SnJ wildtype (WT) mice. Experiments 
using EAAT subtype-specific inhibitors demonstrated that in both WT and PrP 
KO astrocytes, the majority of transport was mediated by EAAT1. Furthermore, 
PrP KO astrocytes were more effective than WT astrocytes at alleviating L-
glutamate-mediated excitotoxic damage in both WT and PrP KO neuronal 
cultures. Thus, in this model, PrP KO astrocytes exerted a functional influence on 
neuronal survival and may therefore influence regulation of glutamatergic 
neurotransmission in vivo. 
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Introduction 
 Prion protein (PrP) is an evolutionarily conserved, 
glycophosphatidylinositol-anchored membrane protein expressed in the 
mammalian nervous system, as well as in many other tissues. Expression in the 
CNS begins early in development and remains throughout adulthood (Miele et 
al., 2003). Despite its wide expression, the function of PrP remains enigmatic. 
While PrP knockout mice (PrP KO) do not suffer from overt disturbances in 
development or behavior (Bueler et al., 1992; Manson et al., 1994), they do 
exhibit subtle abnormalities which suggest PrP involvement in various cellular 
processes including neuroprotection against oxidative stress, support for neurite 
outgrowth, and maintenance of myelinated axons (reviewed in Aguzzi et al., 
2008). In particular, PrP KO mice suffer from deficits in hippocampal spatial 
memory (Criado et al., 2005) and NMDA receptor-related neurophysiological and 
behavioral abnormalities, suggestive of a function of PrP within the glutamatergic 
synapse (Collinge et al., 1994; Manson et al., 1994; Carleton et al., 2001; 
Mallucci et al., 2002; Criado et al., 2005; Khosravani et al., 2008). These 
dysfunctions in PrP KO mice could be attributable to a variety of underlying 
mechanisms involving aberrant signaling through glutamate receptors on 
neurons and/or abnormal neurotransmitter regulation by glutamate transporters 
on astrocytes. 
 One of the major functions of astrocytes is to sequester the excitatory 
neurotransmitter L-glutamate intracellularly and thereby regulate activation of 
excitatory amino acid receptors (Anderson and Swanson, 2000; Bridges and 
Esslinger, 2005; Eulenburg and Gomeza, 2010). Clearance of L-glutamate is 
primarily mediated by high affinity, sodium-dependent excitatory amino acid 
transporters (EAATs). Two of the five identified transporter isoforms, EAAT1 and 
EAAT2, are highly expressed on astrocytes in the cerebellum, hippocampus and 
cerebral cortex. Both transporters are located on glial plasma membranes in 
close apposition to the neuropil and, in combination, are responsible for the bulk 
of L-glutamate transport in the CNS (Danbolt, 2001). The EAATs play a pivotal 
role in controlling excitatory signaling as highlighted both by their anatomical 
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specificity (Anderson and Swanson, 2000) and ability to protect neurons from 
glutamate-mediated excitotoxicity (Robinson et al., 1993; Rothstein et al., 1996).  
An inability of astrocytes to regulate L-glutamate neurotransmission might 
lead to deficits in excitatory neurotransmission and, in particular may contribute 
to deficits observed in PrP KO mice. In the present experiments, we carried out 
detailed kinetic studies on EAAT-mediated glutamate transport in astrocytes 
prepared from C57BL/10SnJ wildtype (WT) mice and from PrP KO mice 
containing 98.5% sequence identity to the C57BL/10SnJ genotype. We found 
that astrocytes from PrP KO mice exhibited higher rates of sodium dependent 
transport of the EAAT-selective substrate D-aspartate than did astrocytes from 
WT PrP expressing mice. Using inhibitors selective for EAAT subtypes, we 
examined the type of transporters functional in both PrP KO and WT astrocytes 
and investigated whether PrP related changes in activity could influence neuronal 
vulnerability to glutamate-mediated excitotoxicity. These results provide a 
potential explanation for the behavioral abnormalities observed in PrP KO mice. 
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Materials and Methods  
Animals.  
C57BL/10SnJ mice (WT) were purchased from Jackson Labs (Bar Harbor, 
ME). Homozygous PrP null (PrP KO) mice on the 129/Ola background (Manson 
et al., 1994) were backcrossed nine times to C57BL/10SnJ mice selecting for the 
PrP KO allele by PCR identification at each cross (Race et al., 2009). Single 
nucleotide polymorphism (SNP) analysis was performed on DNA from PrP KO 
mice, and results were compared to DNA from C57BL/10SnJ mice (Taconic 
Farms Inc., Rensselaer, NY). Non-C57BL/10SnJ SNPs, i.e. from the 129/Ola 
mouse strain donor of the knockout Prnp gene, were identified only on 
chromosome 2, adjacent to the Prnp gene locus. 
Astrocyte and Neuron Cell Cultures.  
Mixed glial cells were harvested from the cortices of WT and KO 1-2 day 
old mice using modifications of the method of McCarthy and de Vellis (McCarthy 
and de Vellis, 1980).  Cortices, with meninges removed, were triturated, plated in 
T-25 flasks with DMEM/F12 (Invitrogen, Carlsbad, CA) containing 15% fetal 
bovine serum (HyClone, Omaha, NE) and maintained in a 5% CO2 incubator at 
37°C. Approximately seven days later, when cultures were confluent, microglia 
and oligodendrocytes were removed from the astrocyte cultures by orbital 
shaking (overnight, 250 rpm). Purified astrocyte cultures were harvested with 
trypsin. For D-aspartate uptake assays, astrocytes were reseeded at 1 x 105 
cells/well in 12 well plates and maintained with fresh media every three days. In 
some experiments, astrocytes were assayed seven days post-seeding, upon 
reaching confluence. In other experiments, confluent cultures were treated with 
0.25mM dibutyryl cyclic AMP (dbcAMP) (Sigma Aldrich, St. Louis, MO) for an 
additional ten days with media changes including dbcAMP every three days. The 
inclusion of dbcAMP induces biochemical and morphological changes more 
representative of astrocytes in vivo including greater EAAT expression (Schlag et 
al., 1998). Consistent with other reports (Schlag et al., 1998), we found that 
treatment with dbcAMP significantly increased EAAT1 and EAAT2 expression as 
judged by analysis of mRNA by quantitative PCR (Figure 3). 
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Primary cortical neurons were prepared essentially as described by Kaech 
and Banker (Kaech and Banker, 2006). Briefly, whole cerebral neocortices 
removed from either WT or PrP KO embryos (14-16 days gestation) were 
digested for 30 minutes with 0.25% trypsin (Invitrogen, Carlsbad, CA) and 
washed four times in Hanks Balanced Salt Solution (HBSS) (Invitrogen, 
Carlsbad, CA).  Cells, 5 x 104 cells/well, were plated onto a bed of 2.5 x 104 
purified astrocytes that had been plated in 24 well plates two days earlier. 
Neuron cultures were initially seeded in MEM with 10% heat - inactivated horse 
serum (HyClone, Omaha, NE) and 0.25% glucose. The media was completely 
replaced 6 hours later with Neurobasal media (500µl) (Invitrogen, Carlsbad, CA) 
supplemented with Glutamax (Invitrogen, Carlsbad, CA), B-27 with antioxidants 
(Invitrogen, Carlsbad, CA) and 5µM cytosine arabinoside (Sigma Aldrich, St. 
Louis, MO) to halt cell proliferation. Cells were fed once at day 7 by replacing half 
the media with fresh media. Neuronal cultures were used 14 days later, 
coinciding with NMDA receptor expression (Choi et al., 1987).  
PrP immunocytochemistry. 
 PrP staining was performed on live primary astrocytes using a 1:1000 
dilution of humanized monoclonal anti-PrP antibody D13 (Williamson et al., 
1998). Following 1 hour incubation at room temperature, cells were fixed in 3.7% 
formaldehyde in PBS for 20 minutes, washed in PBS, permeabilized in 0.1% 
Triton x100, 0.1% sodium citrate for ten minutes, washed in PBS and labeled 
with rabbit anti-GFAP (1:1500) (Dako, Carpinteria, CA) followed by Alexa 
Fluor568 conjugated goat anti-rabbit IgG (1:3000) (Invitrogen, Carlsbad, CA) to 
identify astrocytes and Alexa Fluor488 goat anti-human IgG (1:3000) (Invitrogen, 
Carlsbad, CA) to visualize PrP staining. Fluorescent images were photographed 
on an upright microscope (Olympus BX51) with a 10X objective using Microsuite 
Analysis software. Control wells stained with secondary antibodies alone did not 
show immunofluorescence.  
Surface PrP staining and FACS analysis. 
 Purified WT and KO astrocytes were rinsed with PBS and removed from 
T-25 flasks by incubation with 5mM EDTA for 15 minutes at 37°C. PrP staining 
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was performed on 200,000 live primary astrocytes using 1 µg monoclonal 
antibody D13, specific for PrP, in 50µL PBS. Following 1 hour incubation at 37°C, 
cells were fixed in 3.7% formaldehyde in PBS for 20 minutes, blocked in 0.1M 
glycine in PBS for 30 minutes and incubated for 1 hour at RT with 1 µg Alexa 
Fluor488 goat anti-human IgG (Invitrogen, Carlsbad, CA) in 50µL PBS. Control 
tubes of WT and KO astrocytes were fixed, blocked and incubated with Alexa 
Fluor488 goat anti-human IgG alone. Data was collected by FACSCanto II flow 
cytometer (Becton Dickinson, San Jose CA) and analyzed using FlowJo (Tree 
Star, Ashland, OR). 
Na+ dependent D-aspartate uptake assays.   
Confluent astrocytes in 12 well plates were rinsed with a physiological 
transport buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM KCl, 0.4 mM KH2PO4, 
0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH 7.4) and 
pre-incubated at 37 °C for 5 min. Transport rates were determined using 3H-D-
aspartate, which is effectively transported as an EAAT substrate, yet not 
metabolized by cells following uptake (Koch et al., 1999). Transport assays were 
carried out in which uptake was initiated by replacing the preincubation buffer 
with buffer containing 3H-D-aspartate (5-300µM, 2-12µCi/ml). Following a five-
minute incubation, uptake was terminated by 3 consecutive washes with ice-cold 
buffer. Cells were lysed with 0.4N NaOH for 24 hours and analyzed for 
radioactivity by liquid scintillation counting and for protein by the bicinchoninic 
acid method (Pierce, Rockford, IL). Uptake [pmol D-asp/min/mg protein] was 
calculated and corrected for background radiolabel accumulation at 4°C. 
Previous studies confirmed that uptake measured under these conditions was 
linear with respect to time and protein content (Esslinger et al., 2005). Values are 
reported as mean + SEM pmol/min/mg with each “n” value equaling the number 
of determinations, each done in duplicate. Data was fit to the Michaelis-Menten 
equation using non-linear regression (Prism 5). Transport of D-aspartate was 
also measured in the presence of selective EAAT inhibitors: L-serine-O-sulfate 
(LSOS) (Sigma Aldrich, St. Louis, MO), dihydrokainate (DHK) (Tocris Bioscience, 
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Ellisville, MO), and TBOA (Tocris Bioscience, Ellisville, MO)), which were added 
simultaneously at the indicated concentrations with 5µM 3H-D-aspartate.  
Quantitative RT-PCR Analysis.   
Purified astrocytes, 1 x 104, were seeded onto 24 well plates. Upon 
reaching confluence, some wells were treated with 0.25mM dbcAMP for an 
additional ten days. Confluent astrocytes were harvested with trypsin and lysed 
using Qiashredder (Qiagen, Valencia, CA). Neuron – astrocyte cocultures as 
described above were also harvested with trysin and lysed using Qiashredder 
after 14 days in vitro. Total RNA was isolated using RNeasy mini kit with DNAse 
treatment (Qiagen, Valencia, CA). RNA was reverse-transcribed into cDNA using 
reverse transcription reagents with random hexamers (Applied Biosystems, 
Foster City, CA). The cDNA product was then amplified in a new tube using gene 
expression assays specific for the EAAT1 gene (Slc1a3), EAAT2 gene (Slc1a2), 
and mouse β-actin gene (Applied Biosystems, Foster City, CA). Gene expression 
was quantified using the first cycle number at which each sample reached a fixed 
fluorescence threshold (CΤ). The quantity of expression of each gene was 
normalized to mouse β-actin (∆ CΤ). Fold expression = 2 -∆ CΤ 
Immunoblotting 
Purified WT astrocyte cultures were washed briefly in 5ml cold PBS. 
Astrocytes were lysed by shaking incubation with 1ml cold lysis buffer (5mM Tris 
HCl p.H 7.4, 150mM NaCl, 5mM EDTA, 0.5% Triton X-100, 0.5% deoxycholate, 
1X Protease Inhibitor Cocktail) at 4°C for 5 minutes. Cell lysates were placed in a 
pre-cooled 1.5ml centrifuge tube and centrifuged at 100g for 15 minutes. 
Supernatants were collected and stored at -20°C. Protein concentration was 
quantified using the bicinchoninic acid method (Pierce, Rockford,IL). cell lysates 
(10ug) were boiled in 1X Sample Buffer containing Reducing Agent (Invitrogen, 
Carlsbad, CA) for 3 minutes and loaded onto 4-12% Bis Tris gels (for EAAT1) 
and 12% Tris-Glycine gels (for EAAT2). 4-12% Bis-Tris gels, used for assessing 
monomeric and multimeric EAAT2 that runs at 64kDa and above, were run at 
120 V for 4 hours in MOPS buffer. Proteins were electrophoretically transferred 
onto a polyvinylidene fluoride membrane (37V, O/N). Membranes were blocked 
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in TBS with 0.1% tween 20 containing 5% milk. Membranes were probed with 
either antibodies specific for EAAT1 (1:2000, Tocris Cookson, St. Louis MO), or 
actin (1:10,000, Sigma Aldrich, St. Louis, MO) in TBS–tween for one hour at 
room temperature. Following three ten-minute washes with TBS-tween, 
membranes were probed with appropriate horseradish peroxidase conjugated 
secondary antibodies (EAAT 2 goat anti rabbit (1:3000); actin: goat anti-mouse 
(1:3000)) diluted in TBS tween for one hour at room temperature. Visualization 
was performed using chemiluminescence, according to manufacturer’s 
recommendations (GE Healthcare Life Sciences, Pittsburg, PA). 
 
L-Glutamate-mediated excitotoxicity. 
At 14 days in vitro, neuron-glial co-cultures were exposed to varying 
concentrations of L-glutamate (10-50µM) in 500µl fresh Neurobasal (Invitrogen, 
Carlsbad, CA) media for ten minutes at room temperature. Following exposure, 
cells were gently rinsed with HBSS, after which half their original media (250µl) 
was added back to the well combined with 250µl fresh Neurobasal media with 
B27 supplement to maintain original culture conditions. Twenty-four hours 
following L-glutamate exposure, surviving neurons were enumerated. Cells were 
fixed with 3.7% formaldehyde for 15 minutes, washed with PBS, permeabilized 
with 0.1% Triton x100, 0.1% sodium citrate for ten minutes rinsed with PBS, and 
labeled with mouse anti- MAP2 (1:1000) (Millipore, Billerica, MA) to identify 
neurons followed by incubation with Alexa Fluor 488 conjugated goat anti- mouse 
IgG (1:3000) (Invitrogen, Carlsbad, CA). Nuclei were visualized by incubation 
with DAPI (Invitrogen, Carlsbad, CA).  To count neurons, three randomly chosen 
fields per well were photographed. The surviving MAP2-positive neuronal cell 
bodies that colocalized with DAPI stained nuclei were quantified (Shin et al., 
2005). Neuronal survival following L-glutamate exposure was expressed as 
percent survived relative to the total number of neurons counted in wells that had 
not been exposed to L-glutamate. Data were obtained from 4 independent co-
culture experiments. 
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Statistical Analysis 
Statistical analysis was performed using non-parametric Mann-Whitney tests. 
Calculations were performed on Prism GraphPad software (version 5). Statistical 
significance was reported for values P<0.05.  
 
 
Results  
PrP expression on primary astrocytes 
To confirm PrP expression on WT primary C57BL/10 astrocytes in vitro, 
cortical astrocytes were purified from 1-2 day old mice and cultured in vitro for 7 
days as described in Methods. Astrocytes from PrP KO mice were used as 
negative controls. Cells were labeled with anti-GFAP, to identify astrocytes, and 
with a monoclonal antibody, D13, reactive with PrP.  As expected, the majority of 
cells in both WT and PrP KO cultures were astrocytes and PrP immunoreactivity 
was only observed on WT astrocytes and not on PrP KO astrocytes  (Figure 2-
1A). Primary WT and PrP KO astrocytes were also examined by flow cytometry 
where live cells were labeled with D13. Surface expression of PrP was only 
observed on WT astrocytes (Figure 2-1B).  
 
Figure 2-1 
Comparison of PrP expression on primary astrocytes harvested from WT and PrP KO mice 
 A. Live primary astrocytes from WT and PrP KO mice were labeled with anti-PrP monoclonal 
antibody, D13 (green), fixed, permeabilized and labeled with anti-GFAP, specific for astrocytes 
(red). Primary antibodies were visualized following incubation with Alexa Fluor-conjugated 
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secondary antibodies as described in Methods. Nuclei were stained with DAPI. Results show 
strong PrP staining on the cell surface of WT astrocytes and no PrP staining on PrPKO 
astrocytes. 
B. Study of surface PrP expression on WT and PrP KO primary astrocytes by flow cytometry. Live 
astrocytes were labeled with primary antibody, D13 anti-PrP. D13 immunoreactivity was 
measured by FACS following fixation and incubation with an Alexa Fluor-conjugated secondary 
antibody as described in Methods. Graph shows cell frequency plotted versus fluorescence 
intensity. WT astrocytes showed strong cell surface PrP staining and KO astrocytes showed no 
detectable PrP staining.  
 
Comparison of EAAT activity in WT and PrP KO astrocytes  
We next examined the potential influence of PrP expression on L-
glutamate homeostasis by analyzing EAAT–mediated transport by astrocytes 
prepared from WT and PrP KO mice. Both EAAT1 and EAAT2 are localized to 
astrocytes and are known to be responsible for the bulk of CNS glutamate 
transport (Danbolt, 2001). Sodium-dependent transport assays were performed 
using the non-metabolized EAAT substrate, D-aspartate, at a range of 
concentrations. As shown in Figure 2-2A, transport rates between WT and PrP 
KO astrocytes clearly diverged at concentrations of D-aspartate greater than 
50µM. When fit to the Michaelis Menten equation, the Vmax values were 1.7 fold 
higher in the PrP KO astrocytes compared to WT astrocytes (687 vs. 407 
pmol/min/mg, Table 1-1 and Figure 2-2C).  
Previous studies have demonstrated that treatment of primary astrocytes 
with dibutyryl-cyclic AMP (dbcAMP) produces morphological and biochemical 
changes more representative of astrocytes found in vivo (e.g. increased 
expression of EAATs, GFAP, glutamine synthetase, and neurotransmitter 
receptors) (Khelil et al., 1990; Le Prince et al., 1991; Miller et al., 1994; Jackson 
et al., 1995; Hosli et al., 1997; Swanson et al., 1997; Schlag et al., 1998; 
Daginakatte et al., 2008). Therefore, we also studied WT versus PrP KO 
astrocytes treated for ten days with dbcAMP (0.25mM).  Initial experiments also 
confirmed that transport rates in the untreated cells were not significantly altered 
by the additional ten days in culture (data not shown).  When dbcAMP-treated 
astrocytes were stained with D13 anti PrP, PrP immunoreactivity was only 
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observed in WT astrocytes (data not shown). In transport experiments, PrP KO 
astrocytes treated with dbcAMP exhibited a 2.5 fold increase in Vmax for D-
aspartate transport when compared to WT astrocytes treated with dbcAMP (1768 
vs. 697 pmol/min/mg, Figure 2-2B, Figure 2-2D, and Table 2-1). This increase 
was larger than the 1.7 fold increase observed in untreated astrocytes (Table 2-
1).  Thus, the highest Vmax for  D-aspartate transport were found in cells lacking 
PrP that had been treated with dbcAMP.  
Though differences in Vmax were observed between WT and PrP KO 
astrocytes both before and after treatment with dbcAMP, Km values were only 
significantly different when astrocytes were cultured with dbcAMP (66 vs. 173µM, 
Table 2-1).  Alterations in Vmax values may reflect changes in either transporter 
activity or expression. However, the observed change in Km between WT and 
PrP KO astrocytes following dbcAMP treatment suggest that factors associated 
with PrP may have a direct influence on transporter activity in the differentiated 
cells.  
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Figure 2-2  
Comparison of D-aspartate transport by EAATs in WT and PrP KO astrocytes. 
A. EAAT activity was measured in primary astrocytes derived from WT and PrP KO neonatal 
mice cultured 7 days post-harvest. Astrocytes were incubated with 5µM, 10µM, 30µM, 75µM or 
150µM D-aspartate, a non-metabolized analog of L-glutamate, for 5 minutes. Transport rate at 
each concentration was measured (solid and open circles) and then fit to the Michaelis Menten 
equation using non-linear regression (solid and dashed curves). Results are averages of data 
from multiple independent observations (N=13 for WT, N=9 for PrP KO). Results show faster 
transport by PrP KO astrocytes.  
B. EAAT activity was measured in primary astrocytes, which were cultured in the presence of 
dbcAMP for an additional 10 days. This treatment induced morphological and biochemical 
changes in astrocytes including the increase in number of functional transporters. Astrocytes 
were incubated with 5µM, 10µM, 30µM, 75µM, 150µM or 300µM D-aspartate for 5 minutes. As 
expected, transport rates increased in both WT and PrP KO astrocytes (note the scale bar 
difference between Figure 2-2A and 2-2B). Transport rate at each concentration of D-aspartate 
(solid and open circles) was fit to the Michaelis Menten equation using non-linear regression 
(solid and dashed curves). Data are averages of multiple independent observations (N=11 for 
WT, N=9 for PrP KO). Results show faster transport by PrP KO astrocytes.  
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C. The Vmax of EAAT-mediated transport for each experiment examining primary astrocytes 7 
days post harvest is shown. WT astrocytes are respresented with solid circles and KO astrocytes 
represented as solid squares.  Results show higher Vmax values in PrP KO astrocytes. 
D. Similar to 2-2C, the Vmax of EAAT-mediated transport for each experiment is shown examining 
primary astrocytes treated with dbcAMP for ten additional days. Results show higher Vmax values 
in dbcAMP-treated PrP KO astrocytes.  
 
Table 2-1. Kinetics of D-aspartate transport in WT and PrP KO 
astrocytes 
Genotype Treatment n Km1 Vmax2 
Fold 
Change3 
WT None 13 40 + 8 407 + 29 
KO None 9 63 + 19 687 + 614 
1.7 + 0.19 x 
WT dbcAMP 11 66 + 10 697 + 57 
KO dbcAMP 9 173 + 296 1768 + 1005 
2.5 + 0.2 x 
 
Data from Figure 2-2 were fit by non-linear regression to the Michaelis 
Menten equation. n is the number of independent observations. Vmax and Km 
values are mean + SEM. 
1 µM 
2 pmol/min/mg protein 
3 Fold increase in Vmax 
4 p = 0.0007, comparison of Vmax in WT vs. PrP KO astrocytes. All statistics 
were done using non-parametric Mann-Whitney u-test. 
5 p = 0.0005, comparison of Vmax in dbcAMP-treated WT vs. PrP KO 
astrocytes 
6p = 0.002, comparison of Km in dbcAMP-treated WT vs. PrP KO astrocytes. 
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Evaluation of EAAT1 and EAAT2 expression and activity in WT and PrP KO 
astrocytes 
 The increased Vmax values for transport observed in PrP KO astrocytes 
could be due to alterations in transporter expression levels. Quantitative RT-PCR 
was performed using mRNA from WT and PrP KO astrocytes. In untreated 
astrocytes, EAAT1 expression was approximately 16-fold higher than EAAT2 
expression (30% vs. 2% of actin expression, Figure 2-3A). As expected, 
dbcAMP-treated astrocytes showed increased expression of both EAAT1 and 
EAAT2 mRNA (Schlag et al., 1998). In dbcAMP treated astrocytes, EAAT1 
expression was approximately 12.5-fold higher than EAAT2 (100% vs. 7% of 
actin expression, Figure 2-3A). Therefore EAAT1 appeared to be the major 
transporter observed in both untreated and dbcAMP-treated astrocytes. In 
addition, EAAT1 mRNA levels were similar in PrP KO vs. WT astrocytes, and 
likewise, EAAT2 mRNA levels were similar in these same cells (Figure 2-3A). 
Therefore the increased transport observed in PrP KO astrocytes compared to 
WT astrocytes did not correlate with increased production of either EAAT1 or 
EAAT2 transporter mRNA. 
Though dbcAMP treatment produces morphological and biochemical 
changes more representative of astrocytes in vivo, including an increase of both 
EAAT1 and EAAT2, co-culture with neurons can specifically induce EAAT2 
expression (Gegelashvili et al., 1997; Swanson et al., 1997). Therefore, we also 
evaluated EAAT subtype expression in WT and PrP KO astrocyte-neuron co-
cultures. Co-culture with neurons increased EAAT2 expression to 30% of actin 
expression, which was also detectable at the protein level (Figure 2-3B). 
However, EAAT1 expression was also increased in astrocyte-neuron co-cultures 
to 100% of actin expression, though upregulation did not differ from what was 
observed in dbcAMP astrocytes. Despite a 10-fold increase in EAAT2 expression 
specific to co-culture with neurons, however, EAAT1 mRNA expression was still 
higher than EAAT2 expression (100% vs. 30% of actin expression).  
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B. 
 
 
Figure 2-3 EAAT expression in WT and PrP KO astrocytes 
A. Analysis of EAAT1 and EAAT2 in WT and PrP KO astrocytes by real time RT-PCR. 
EAAT1 and EAAT2 mRNA levels were quantified in WT and PrP KO (KO) astrocytes 7 days 
following purification (as defined in Methods), following an additional 10 day treatment with 
0.25mM dbcAMP (as described in Methods) or following 14 day co-culture with neurons of the 
same genotype. Values shown are average ∆CT+ SEM of four - seven cultures where results 
were normalized to mouse ß actin. A low ∆CT value corresponds to higher amount of transcript 
detected. Though dbcAMP treatment and co-culture with neurons increased EAAT2 expression, 
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EAAT1 expression was always higher in astrocyte cultures. In no comparison did PrP KO and WT 
astrocytes differ from each other significantly in EAAT mRNA expression. 
B. Immunoblot of EAAT2 in WT astrocytes. EAAT2 immunoblot of lysates prepared from 
astrocytes 7 days following harvest (A) or following 14 day co-culture with WT neurons (A+N). 
EAAT 2 expression, which is undetectable in primary astrocytes, is upregulated when astrocytes 
are co-cultured with neurons.   
 
 To assess the contribution of individual EAAT subtypes to the total 
observed transport of D-aspartate in WT and PrP KO astrocytes, transport of 
5µM D-aspartate was measured in the presence of inhibitors that preferentially 
act on individual EAAT subtypes (Bridges and Esslinger, 2005). In each of the 
cultures, activity was markedly reduced in the presence of EAAT1 selective 
inhibitor, LSOS (i.e. remaining activity was 20-30% of control measurements in 
the presence of 500µM LSOS, Table 2-2).  Consistent with these results, the 
inclusion of the EAAT2 selective inhibitor, dihydrokainate (DHK, 
300µM), produced much less inhibition and the remaining activity ranged from 
73-89% of control (Table 2-2).  Thus, the majority of uptake observed was 
mediated by EAAT1 as predicted by our mRNA expression data (Figure 3A and 
3B). This was similar to previous reports of primary in vitro astrocyte cultures, 
including those treated with dbcAMP (Duan et al., 1999; Munir et al., 2000; Lin et 
al., 2001; Adolph et al., 2007).  
Because of the marked increase in EAAT2 mRNA expression observed in 
astrocyte-neuron co-cultures, the pharmacological profile of WT and PrP KO co-
cultures was also assessed. In all co-cultures, D-aspartate activity was markedly 
reduced in the presence of EAAT1 selective inhibitor, LSOS (i.e. remaining 
activity was 20-32% of control measurements, Table 2-2), while activity in the 
presence of EAAT2 selective inhibitor, DHK, produced much less inhibition (i.e. 
remaining activity was 73-77% of control measurements, Table 2-2). Thus, while 
EAAT2 mRNA and protein expression was increased in these co-cultures, its 
contribution to L-glutamate transport was masked by the high amounts of EAAT1 
expression. 
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Table 2-2. D-aspartate transport in WT and PrP KO astrocytes in the 
presence of various EAAT inhibitors 
 
 
 
% activity retained in the presence of EAAT 
Inhibitors1 
Genotype    Treatment2 D-asp transport
3         
(pmol/min/mg) 
LSOS    
(EAAT1) 
DHK 
 (EAAT2) 
TBOA  
(EAAT 1-5) 
WT  None 30 + 2 18 + 4 % 76 + 11 % 7 + 4 % 
PrP KO  None 31 + 3 20 + 4 % 89 + 8 % 8 + 4 % 
WT dbcAMP 39 + 7  30 + 6 % 82 + 6 % 11 + 3 % 
PrP KO dbcAMP 38 + 2 26 + 3 % 73 + 13 % 9 + 3 % 
WT Neurons 25 + 0 32 + 1 % 77 + 5 % 6 + 2 % 
PrP KO Neurons 27 + 0 20 + 1 % 73 + 8 % 5 + 2 % 
 
1 Na+ dependent transport of 5µM D-aspartate was measured in the presence of 
500µM LSOS, 300µM DHK or 500µM TBOA. These blockers were included in 
the assays at concentrations estimated to block at least 80% of either EAAT1 or 
EAAT2 activity. TBOA was used as a control for maximal inhibition with 
specificity for both EAAT1 and EAAT2. Activity retained (% control) is shown as 
mean + SEM of four independent observations.  
2 WT and PrP KO were cultured for 7 days as described in Method, treated for an 
additional ten days with 0.25mM dbcAMP to increase EAAT expression or were 
cultured in the presence of neurons, as described in Methods for 14 days. 
3 transport was measured at a concentration of 5µM D-aspartate. 
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Comparison of sensitivity of WT and PrP KO neurons to glutamate-
mediated excitotoxicity 
 Numerous studies have concluded that inadequate clearance of L-
glutamate by astrocytes can lead to excitotoxic neuronal death through excessive 
activation of ionotropic excitatory amino acid receptors, especially the NMDA 
subtype (Rosenberg and Aizenman, 1989; Choi, 1992; Speliotes et al., 1994). 
Therefore, we tested the ability of WT and PrP KO astrocytes to protect neurons 
of the same genotype from L-glutamate-mediated excitoxicity in vitro. After 14 
days in culture, coinciding with NMDA receptor expression and the excitotoxic 
vulnerability of neurons, the co-cultures of astrocytes and neurons were exposed 
for ten minutes to L-glutamate at concentrations ranging from 10µM to 50µM. 
The number of surviving neurons was quantified based on MAP2 
immunoreactivity 24 hours later as previously described by Shin et al (Shin et al., 
2005). Compared to untreated controls, exposure to 20µM L-glutamate caused a 
slight reduction in the number of both WT and PrP KO neurons (Figure 2-4A and 
2-4B), although the morphology of WT and PrP KO neurons remained similar to 
untreated controls (not shown). In contrast, exposure to 30µM and 40µM L-
glutamate led to significantly reduced survival of neurons in the WT cultures 
compared to neurons in the PrP KO cultures (Figure 2-5A). Furthermore, the 
surviving neurons exhibited a decreased number of neurites and altered neurite 
morphology (Figure 2-4C-F). At 50µM L-glutamate, both WT and PrP KO cultures 
showed similar damage (Figure 2-4G and 2-4H). Thus, the increased EAAT 
activity observed in the PrP KO cultures correlated with an increased resistance 
to damage by a window (30µM and 40µM) of L-glutamate concentrations 
compared to WT neurons cultured with WT astrocytes. 
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Figure 2-4 
Neuronal sensitivity to L-glutamate-mediated excitotoxicity.  
Neuronal cultures derived from WT or PrP KO mice (gestational period 14-16) were plated onto a 
bed of purified WT or PrP KO astrocytes, respectively, and co-cultured for 14 days as described 
in Methods. On day 14, coinciding with NMDA receptor expression, co-cultures were exposed to 
20µM (A-B), 30µM (C-D), 40µM (E-F) and 50µM (G-H) L-glutamate for 10 minutes. 24 hours 
following exposure, co-cultures were fixed, permeabilized, and stained with anti-MAP2 to identify 
neurons. MAP2 staining was visualized following incubation with an Alexa Fluor-conjugated 
secondary antibody. Nuclei were visualized with DAPI. WT neurons showed more damage than 
PrP KO neurons at glutamate concentrations of 30 and 40µM.  
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Figure 2-5 
Increased astrocytic protection against L-glutamate-mediated excitotoxicity by PrP KO 
astrocytes. 
A. Percent of MAP-2-positive WT or PrP KO neurons in neuron/astrocyte co-cultures 24 hours 
following a ten minute L-glutamate exposure (30µM or 40µM). The data (mean + SEM) were 
obtained from four independent co-culture experiments. Results show increased toxicity in 
cultures with WT neurons co-cultured with WT astrocytes. Cultures of WT neurons and PrP 
KO astrocytes showed significantly less toxicity. Experiments in which PrP KO neurons were 
plated on WT astrocytes yielded variable results (data not shown), which are most likely the 
result of contaminating PrP KO astrocytes from preparations of PrP KO neurons.  
B. Percent of MAP-2 positive neurons in neuron/astrocytes co-cultures 24 hours following a ten 
minute exposure to NMDA. The data (mean + SEM) were obtained from three independent 
co-culture experiments as described in panel A. In the presence of NMDA, increased 
neurotoxicity was seen in PrP KO co-cultures compared to WT co-cultures. 
 
We next examined if PrP KO astrocyte cultures could similarly provide 
increased protection to WT neurons. WT neurons were grown on a bed of 
purified PrP KO astrocytes in the presence of 5µM cytosine arabinoside (as 
described in Methods) to prevent WT astrocyte contamination and growth. After 
exposure to 30µM and 40µM, WT neurons exhibited a higher degree of survival 
when cultured on PrP KO astrocytes than when cultured on WT astrocytes 
(Figure 2-5A). The levels of survival were similar to those observed when PrP KO 
neurons were cultured with PrP KO astrocytes (Figure 2-5A). These data 
demonstrated that PrP KO astrocytes were able to uniformly lessen the extent of 
excitotoxic neuronal loss in both WT and PrP KO co-cultures. 
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A previous report showed that PrP KO neurons were more vulnerable to 
excitotoxicity than WT neurons when NMDA was used to induce the insult 
(Khosravani et al. 2008). This was opposite to the results we observed using L-
glutamate as the excitotoxic agonist. To study whether these differences might 
be due to methodological differences or, more likely, to the inability of EAATs to 
clear NMDA from the extracellular space, we tested the vulnerability of our 
cultures to NMDA.  When 1mM NMDA was added to our cultures in place of L-
glutamate, KO neurons had a lower survival than did WT neurons (Figure 2-5B), 
consistent with Khosravani et al. Taken together, these results suggest that 
because L-glutamate is an EAAT substrate, the increased clearance by PrP KO 
astrocytes functioned to counteract the oversensitivity of PrP KO neurons to 
stimulation by excitatory receptor agonists. 
 
Discussion 
In our kinetic and pharmacological characterization of primary astrocyte 
cultures, we observed increased EAAT activity in cells from PrP KO mice 
compared to PrP expressing WT mice. This finding was observed in astrocytes 
cultured both in the absence and presence of dbcAMP, which has been shown to 
induce biochemical and morphological characteristics of astrocytes observed in 
vivo (Khelil et al., 1990; Le Prince et al., 1991; Miller et al., 1994; Jackson et al., 
1995; Hosli et al., 1997; Swanson et al., 1997; Schlag et al., 1998; Daginakatte et 
al., 2008). Furthermore, increased transport by PrP KO astrocytes was shown to 
be functionally significant as KO astrocytes protected both KO and WT neurons 
from L-glutamate-mediated excitotoxicity to a greater extent than did WT 
astrocytes. Levels of L-glutamate are believed to reach millimolar levels in the 
synaptic cleft during excitatory transmission (Clements et al., 1992) and are 
rapidly cleared to markedly lower (0.1-1µM) homeostatic levels (Herman and 
Jahr 2007). Therefore, the differences in Vmax observed between PrP KO and WT 
astrocytes could have a marked influence on transmitter clearance and 
glutamatergic signaling.  
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Though the kinetic and physiological data clearly suggests that PrP KO 
astrocytes have a greater capacity to transport L-glutamate, the underlying 
mechanisms for increased EAAT activity have been difficult to ascertain.  We 
observed increased EAAT1 and EAAT2 activity in PrP KO versus WT astrocytes 
without increased expression of either transporter. Given the very high levels of 
EAAT protein present in these cultures, it has, however, been difficult to 
accurately correlate expression with activity (Schlag et al., 1998). As an 
alternative to higher total levels of EAAT protein, increased activity could be due 
to indirect mechanisms that affect surface expression of the transporters and/or 
changes in intrinsic activity, though we currently do not have data to differentiate 
between these processes. As opposed to the changes in Vmax, the difference in 
Km between dbcAMP-treated WT and PrP KO astrocytes argues for a direct 
modulation of the transporters resulting in changed affinity for L-glutamate.  L-
Glutamate transporters are subject to interactions with modulating proteins 
(Jackson et al., 2001) and posttranslational modifications that can result in 
altered transporter function  (Adolph et al. 2007; Duan et al. 1999; Lin et al. 2001; 
Munir et al. 2000, Schlag et al. 1998). PrP expression may be involved in such 
modifications; we observed an increase in PrP mRNA expression following 
dbcAMP treatment in WT astrocytes. The localization of PrP and EAATs to lipid 
rafts may provide an environment conducive to interaction between these 
molecules (Butchbach et al. 2004; Naslavsky et al. 1997). As functional data 
indicate the majority of the transport quantified in the present experiments. 
Including astrocyte-neuron co-cultures, is mediated by EAAT1, it suggests that it 
is this subtype that is altered in the PrP KO astrocytes and leaves open the 
issues as to whether or not PrP expression may also influence EAAT2 and 
EAAT3.  
In contrast to our findings, a previous study reported that cultures of 
astrocytes expressing PrP transported L-glutamate at a faster rate than did PrP 
KO astrocytes and that this difference was likely attributable to increases in Km 
without a change in Vmax (Brown and Mohn 1999). However, the decease in the 
rate of transport in the PrP KO astrocytes was only reported at a single 
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concentration (100 µM).  A number of methodological differences, including the 
use of 3H-L- glutamate as a substrate rather than 3H-D-aspartate, determinations 
of background and specific uptake, as well as treating the cells with dbcAMP, 
make direct comparisons difficult. The most notable difference between the two 
studies, however, concerns the genetics of the strains used to generate the cell 
cultures. In the Brown and Mohn study, the PrP WT mice were (129/Sv(ev) x 
C57BL/6J) F1 hybrids, while PrP KO mice were homozygous for a random 
mixture of 129/Sv(ev) and C57BL/6J genes. Thus, the background genes of 
these PrP KO mice differed completely from the WT mice used. In contrast, the 
PrP KO mice used in our experiments were backcrossed nine times to 
C57BL/10SnJ mice, which was used as the WT for comparison.  Therefore, in 
our PrP KO mice, only the Prnp (PrP) gene itself and areas immediately adjacent 
to the Prnp gene were still of strain 129/Ola origin. It is possible that these 
adjacent genes might also contribute to the differences observed in our 
experiments.   
Astrocytic EAATs mediate the fine balance between having sufficient L-
glutamate in the synapse for neuronal signaling without exceeding the threshold 
that would trigger excitotoxic pathology. To test if the increased transport 
exhibited by PrP KO astrocytes was physiologically relevant, we studied the 
toxicity of L-glutamate on mixed cortical cultures, where differences in transport 
capacity have previously been shown to modulate susceptibility to excitotoxicity 
(Rosenberg and Aizenman, 1989; Robinson et al., 1993; Rothstein et al., 1996). 
In our experiments, PrP KO astrocytes treated with dbcAMP exhibited the 
highest levels of transport (Table 2-1). Notably, co-culturing astrocytes with 
neurons induces many of the same morphological and biochemical changes 
induced by dbcAMP, including EAAT1 and EAAT2 expression (Gegelashvili et 
al., 1997; Schlag et al., 1998; Perego et al., 2000). When co-cultures contained 
PrP KO astrocytes, we found decreased evidence of excitotoxicity within a 
narrow range of L-glutamate concentrations (Figure 2-5A), suggesting that 
enhanced glutamate transport by PrP KO astrocytes, possibly at the rates seen 
in dbcAMP-treated PrP KO astrocyte cultures, lessened neuronal death. 
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However, this protection from L-glutamate-mediated excitotoxicity is 
distinct from the increased neuronal vulnerability of PrP KO neurons to NMDA-
mediated excitotoxicity observed in our experiments (Figure 2-5B) and by others 
(Khosravani et al 2008).  Exposure to NMDA demonstrated that PrP KO neurons 
are intrinsically more vulnerable than WT neurons to excitotoxic insults induced 
by excessive NMDA receptor activation. While L-glutamate and NMDA are both 
agonists at the NMDA receptor, L-glutamate transporters do not transport NMDA. 
Thus, when NMDA was added to the mixed neuron-astrocyte co-cultures (Figure 
2-5B), the experiment reflected the direct effect of NMDA on PrP KO and WT 
neurons, as the EAATs could not transport NMDA and decrease its effective 
concentration. In contrast, when L-glutamate was added (Figure 2-5A), astrocytic 
transport of L-glutamate was able to alter its concentration, in agreement with the 
D-aspartate uptake measurements, and reduce the excitotoxic challenge.  
Unfortunately, the fragility of neurons precluded direct assays of transport 
capacity in the co-cultures. Thus, increased transport of L-glutamate by PrP KO 
astrocytes appeared to be effective in protecting PrP KO neurons from death 
despite an increased vulnerability to excitotoxic injury. Similar results were 
observed in the G93A SOD1 mouse model of amyotrophic lateral sclerosis where 
a drug-induced increase in EAAT activity (approximately 2-fold) was shown to be 
neuroprotective in vitro and delayed neuronal loss in vivo (Rothstein et al., 2005). 
Increased clearance of L-glutamate by astrocytes in vivo may contribute to 
the neurophysiological abnormalities observed previously in PrP KO mice. For 
example, reduced excitatory post-synaptic potentials (Carleton et al. 2001), 
impaired formation of long-term potentiation (Collinge et al. 1994; Criado et al. 
2005; Manson et al. 1995), reductions in afterhyperpolarization potentials 
(Mallucci et al., 2002) and abnormal responses to NMDA antagonist MK-801 
(Coitinho et al., 2002) observed in PrP KO mice all suggest attenuation of L-
glutamate-mediated signaling. Many of these alterations would be consistent with 
the premature termination of the L-glutamate signal and/or the excessive 
clearance of L-glutamate from the extracellular space surrounding EAA 
receptors. Consistent with such a conclusion, the EAATs have been shown to 
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regulate the extracellular levels of L-glutamate available to activate synaptic and 
extrasynaptic receptors in specific excitatory circuits (Turecek and Trussell, 2000; 
Dzubay and Otis, 2002; Huang et al., 2004; Diamond, 2005). Thus, the impact of 
alterations in EAAT activity may be greatest in those synaptic connections 
ensheathed by astrocytes, where the presence and positioning of the 
transporters has been shown to modulate glutamatergic neurotransmission 
(Anderson and Swanson, 2000; Bridges and Esslinger, 2005; Eulenburg and 
Gomeza, 2010). 
Low EAAT activity has been reported in a number of neurodegenerative 
diseases, including amyotrophic lateral sclerosis (Rothstein et al., 1992), HIV-
associated dementia (Sardar et al., 1999), and Alzheimer’s Disease (Masliah et 
al., 1996). Increased levels of glutamate in the synaptic cleft may lead to 
neuronal death through excitotoxicity (Beart and O'Shea, 2007).  Accordingly, 
enhancement of L-glutamate transport has been regarded as a potential 
therapeutic goal. However, hyperactive EAAT activity and consequent reduced 
NMDA receptor signaling is not without its own complications, as has been 
suggested to be the case in schizophrenia (Miyamoto et al., 2005).  Similarly, the 
present work suggests that increased EAAT activity in the PrP KO mouse may 
contribute to its neurophysiological phenotype. Taken together, therapeutic 
approaches modulating EAAT activity in any disease will require targeting a level 
of transporter activity that will maintain an optimal level of L-glutamate in the 
synaptic cleft, balancing physiological and pathological signaling during all 
phases of neuronal activity.  
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ABSTRACT 
Though the precise function of Prion protein (PrP) is unknown, numerous studies 
suggest a role in glutamatergic neurotransmission. In chapter two, we showed that PrP 
influenced L-glutamate signaling in vitro by impacting its clearance from the vicinity of 
neurons. Therefore, we investigated whether similar localization of PrP and excitatory 
amino acid transporters (EAATs) to lipid rafts influenced astrocytic EAAT activity. 
Astrocytes were harvested from C57BL10 (WT) mice, PrP knockout (PrP KO) mice and 
transgenic mice expressing a non-membrane, GPI anchorless form of PrP (tg88). 
Though hypothesized that EAAT activity in PrP anchorless astrocytes would be the 
same as PrP non-expressing astrocytes, tg88 EAAT activity did not mimic PrP KO 
astrocytic EAAT activity. Further co-immunoprecipitation studies did not reveal a strong 
interaction between WT PrP and EAAT1, the transporter subtype responsible for the 
majority of transport activity in primary astrocytes. Thus, in these models, detectable 
evidence for PrP and EAAT interaction within the lipid raft was not found.  
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INTRODUTION 
Increased EAAT activity in PrP KO astrocytes and the consequent ability to 
reduce neuronal death following exposure to toxic levels of L-glutamate suggested that 
expression of PrP regulated L-glutamate transport (Chapter 2).  This modulation of 
transport could be a result of upstream signaling events including RNA and protein 
expression, unique to PrP expression. However, the association of PrP and the EAATs 
to the plasma membrane may provide a location where these molecules can interact 
 PrP is a cell surface glycoprotein, bound to the outer leaflet of the plasma 
membrane, attached by a GPI anchor (Stahl et al., 1987). GPI linked proteins are 
typically localized to lipid rafts. In agreement, processed PrP is found in detergent 
insoluble, cholesterol rich lipid raft microdomains (Naslavsky et al., 1997). However, the 
physiological relevance of PrP localization to lipid rafts is unknown except in 
susceptibility to TSE diseases (Speare et al., 2010). Attachment to the plasma 
membrane is unique in amyloid diseases; TSEs are the only diseases in which the 
converted protein is GPI anchored. However, transgenic mice that express PrP without 
the GPI anchor (tg44) appear normal and are still susceptible to TSEs although they 
present with markedly different clinical symptoms, pathology and incubation period 
(Chesebro et al., 2005; Chesebro et al., 2010). Presumably, the physiological role of 
PrP takes advantage of lipid raft locale as either an area in which PrP can modulate the 
action of other proteins or, itself, be modulated. 
The EAATs are trimeric, membrane-spanning proteins responsible for buffering 
and transporting L- glutamate from the synaptic space. Astrocytic (EAAT1, EAAT2) and 
neuronal (EAAT3, EAAT4) L-glutamate transporters are localized to cholesterol rich, 
detergent insoluble, lipid rafts (Butchbach et al., 2004). Localization of neuronal L-
glutamate transporters to lipid rafts influences the efficacy of L-glutamate transport 
through the clustering of proteins that can modulate transport. Interaction of GTRAP3–
18 and EAAT3 has been shown to negatively modulate L-glutamate transport (Lin et al., 
2001). In contrast, GTRAP41 and GTRAP48 have been shown to increase EAAT4 
mediated L-glutamate transport (Jackson et al., 2001). To date, lipid raft proteins which 
interact with astrocytic EAATs have not been identified. 
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 In order to understand whether PrP negatively modulates astrocytic EAAT 
activity, the interaction between PrP and EAATs were investigated. Co-
immunoprecipitation experiments were performed investigating whether a strong 
interaction between PrP and the EAATs existed. EAAT activity was also investigated 
comparing astrocytes harvested from mice expressing GPI anchorless PrP (tg88), 
membrane anchored, wild-type PrP (WT) or no PrP at all (PrP KO).  
 
METHODS 
Animals 
 C57BL/10SnJ (WT) mice were purchased from Jackson Labs (Bar Harbor, ME). 
Homozygous PrP knockout (PrP KO) mice on the 129/Ola background (Manson et al., 
1994) were backcrossed nine times to C57BL/10SnJ mice selecting for the PrP KO 
allele by PCR identification at each cross (Race et al., 2009). Transgenic GPI 
anchorless PrP mice (tg44+/−) (Chesebro et al., 2005) were backcrossed to 
C57BL/10SnJ-Prnp−/− mice for six to nine generations with selection for the Prnp−/− 
genotype and the tg44+/− genotype. Heterozygous tg44+/- were then interbred to 
create homozygous transgenic GPI anchorless PrP mice (tg44-/-, also known as tg88). 
Thus these mice expressed anchorless PrP but lacked normal anchored mouse PrP 
allele (Chesebro et al., 2010). 
Astrocyte Cultures 
Mixed glial cells were harvested from the cortices of WT and KO 1-2 day old 
mice using modifications of the method of McCarthy and de Vellis (McCarthy and de 
Vellis, 1980). Cortices, with meninges removed, were triturated, plated in T-25 flasks 
with DMEM/F12 (Invitrogen, Carlsbad, CA) containing 15% fetal bovine serum 
(HyClone, Omaha, NE) and maintained in a 5% CO2 incubator at 37°C. Approximately 
seven days later, when cultures were confluent, microglia and oligodendrocytes were 
removed from the astrocyte cultures by orbital shaking (overnight, 250 rpm). Purified 
astrocyte cultures were harvested with trypsin. For D-aspartate uptake assays, 
astrocytes were reseeded at 1 x 105 cells/well in 12 well plates and maintained with 
fresh media every three days. In some experiments, astrocytes were assayed seven 
days post-seeding, upon reaching confluence. In co-immunoprecipitation experiments, 
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confluent cultures were treated with 0.25mM dibutyryl cyclic AMP (dbcAMP) (Sigma 
Aldrich, St. Louis, MO) for an additional ten days with media changes including dbcAMP 
every three days.  
Na+ dependent D-aspartate uptake assays.   
Confluent astrocytes in 12 well plates were rinsed with a physiological transport 
buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM KCl, 0.4 mM KH2PO4, 0.3 mM 
Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH 7.4) and pre-incubated at 
37 °C for 5 min. Transport rates were determined using 3H-D-aspartate, which is 
effectively transported as an EAAT substrate, yet not metabolized by cells following 
uptake (Koch et al., 1999).Transport assays were carried out in which uptake was 
initiated by replacing the preincubation buffer with buffer containing 3H-D-aspartate (5-
300µM, 2-12µCi/ml). Following a five-minute incubation, uptake was terminated by 3 
consecutive washes with ice-cold buffer. Cells were lysed with 0.4N NaOH for 24 hours 
and analyzed for radioactivity by liquid scintillation counting and for protein by the 
bicinchoninic acid method (Pierce, Rockford, IL). Uptake [pmol D-asp/min/mg protein] 
was calculated and corrected for background radiolabel accumulation at 4°C. Previous 
studies confirmed that uptake measured under these conditions was linear with respect 
to time and protein content (Esslinger et al., 2005). Values are reported as mean + SEM 
pmol/min/mg with each “n” value equaling the number of determinations, each done in 
duplicate. Data was fit to the Michaelis-Menten equation using non-linear regression 
(Graph Pad Prism 5, GraphPad Software Inc, La Jolla, CA). 
Co-immunoprecipitation 
Purified WT astrocyte cultures were washed briefly in 5ml cold PBS. Astrocytes 
were lysed by shaking incubation with 1ml cold lysis buffer (5mM Tris HCl p.H 7.4, 
150mM NaCl, 5mM EDTA, 0.5% Triton X-100, 0.5% deoxycholate, 1X Protease 
Inhibitor Cocktail) at 4°C for 5 minutes. Lysates were placed in a pre-cooled 1.5ml 
centrifuge tube and centrifuged at 100g for 15 minutes. Supernatants were collected 
and stored at -20°C. Protein concentration was quantified using the bicinchoninic acid 
method (Pierce, Rockford,IL). 
Immunoprecipitation of PrP was done by incubating 0.1mg astrocyte lysate with 
0.1M NaCl, antibodies specific for PrP: R30, R20, or R18 at indicated concentrations 
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and co-IP buffer (50mM Tris HCl pH 7.5, 15mM EDTA, 100mM NaCl and 0.1% Triton X-
100 and 1X Halt Protease Inhibitor) to a final volume of 500µL. Antibody-lysate 
complexes were incubated on ice for 90 minutes and occasionally inverted. A Protein A-
sepharose slurry was added to the tubes (50µL) and incubated with rotation for 45 
minutes at 4°C.  Immunoprecipitates were pelleted by centrifugation (1000rpm, 30 
seconds) and washed 3 times with 1 ml co-IP buffer. Immunoprecipitates were collected 
by boiling pellets for 5 minutes, centrifugation to pellet the beads, and collection of the 
supernatant.   
Immunoblot 
 One half of immunoprecipitate eluate or cell lysates (10ug) were boiled in 1X 
Sample Buffer containing Reducing Agent (Invitrogen, Carlsbad, CA) for 3 minutes and 
loaded onto 4-12% Bis Tris gels (for EAAT1) and 12% Tris-Glycine gels (for EAAT2). 4-
12% Bis-Tris gels, used for assessing monomeric and multimeric EAAT1 that runs at 
64kDa and above, were run at 120 V for 4 hours in MOPS buffer. 12% Tris Glycine gels 
that were used to assess PrP expression, which runs at 33 KDa, were run for 1 hour at 
120V. Proteins were electrophoretically transferred onto a polyvinylidene fluoride 
membrane (37V, O/N). Membranes were blocked in TBS with 0.1% tween 20 containing 
5% milk. Membranes were probed with either antibodies specific for EAAT1 (1:2000, 
Tocris Cookson, St. Louis MO), PrP (1:5000, D13, Williamson et al. 1998) or actin 
(1:10,000, Sigma Aldrich, St. Louis, MO) in TBS–tween for one hour at room 
temperature. Following three ten-minute washes with TBS-tween, membranes were 
probed with appropriate horseradish peroxidase conjugated secondary antibodies 
(EAAT 1: goat anti rabbit (1:3000); PrP: rabbit anti human (1:3000); actin: goat anti-
mouse (1:3000)) diluted in TBS tween for one hour at room temperature. Visualization 
was performed using chemiluminescence, according to manufacturer’s 
recommendations (GE Healthcare Life Sciences, Pittsburg, PA).  
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RESULTS 
Immunoprecipitation of PrP does not bring down EAAT1 
 Though PrP KO astrocytes exhibited higher EAAT activity compared to WT 
astrocytes, detectable differences in mRNA expression were not observed, as 
described in Chapter Two. In contrast to transport differences being mediated by 
expression level, it is possible that PrP interacts with the EAATs, decreasing the rate 
transport. Therefore, a direct interaction between PrP and EAAT1, the dominant 
transporter operational in this primary culture system, was investigated.  
PrP was immunoprecipitated from WT astrocyte cultures and protein-protein 
interactions with EAAT1 were investigated. Low amounts of PrP were 
immunoprecipitated when astrocytes were lysed in a non-ionic detergent buffer (Figure 
1). Therefore, astrocytes were lysed in 0.5% sodium deoxycholate, 0.5% Triton X-100 
and incubated alone or in combinations of three polyclonal rabbit antibodies specific for 
PrP – R30 (89-103), R18 (142-155), and R20 (218-232). R30 alone was most efficient 
at immunoprecipitating PrP (Figure 2). The addition of other antibodies in conjunction 
with R30 did not increase the amount of protein immunoprecipitated. Monomeric 
EAAT1, which in primary astrocyte cultures runs at approximately 65 kDa was not 
observed in lysates that had been immunoprecipitated. EAAT 1 was also not co-
immunoprecipitated in primary astrocytes treated with dbcAMP (Figure 3).  The absence 
of EAAT1 co-immunoprecipitates suggested that if any interaction between PrP and 
EAAT1 existed, it was not preserved under these lysis conditions.  
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Figure 3-1.  
Assessment of ionic versus non-ionic detergent containing lysis buffers.  
Two different lysis buffers were investigated to determine which was most effective at solubilizing PrP and 
EAAT1. Astrocyte cultures lysed in a nonionic detergent consisting of 1% Triton-X100 was able to 
solubilize EAAT1 to the same degree as the ionic detergents consisting of either 0.5% sodium 
deoxycholate or 1% sodium deoxycholate, although interestingly, only multimeric forms of EAAT1 was 
detected. In contrast, a marginal amount of PrP was solubilized with the non-ionic detergent compared to 
the amount of PrP solubilized with 0.5% sodium deoxycholate. Therefore, in co-immunoprecipitation 
experiments, 0.5% sodium deoxycholate was used as the astrocyte lysis buffer. 
  
 
 
 66 
 
 
Figure 3-2.  
Co-immunoprecipitation of PrP and EAAT1 in primary WT and PrP KO astrocytes.  
Astrocyte lysates were immunoprecipitated with 5ul and 2.5ul R30, R20 or R18. Lysates were also 
immunoprecipitated with 2.5ul each of two of the above antibodies in combination to see if more PrP 
could be latticed together and pulled down. 5ul and 2.5ul R30 pulled out the greatest amount of PrP from 
WT astrocyte lysates compared to R20 and R18 alone. Compared to R30 alone, a detectable increase in 
the amount of PrP pulled out with antibody combinations containing R30 was not observed. Interestingly, 
the combination of R20 and R18 pulled out more PrP than either R20 or R18 alone. Therefore, R30 was 
the best antibody to use for immunoprecipitating PrP. However, EAAT1 was not detected in any of the 
immunoprecipitates. The band running approximately 50 KDa corresponds to IgG heavy chain.  
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Figure 3-3.  
Co-immunoprecipitation of PrP and EAAT1 in primary WT and PrP KO astrocytes treated with 
dbcAMP. 
Astrocyte lysates were immunoprecipitated with 2.5ul R30 and immunoblotted against PrP and EAAT1. 
EAAT1 was not detected in immunoprecipitated lysates. The band running at approximately 50kDa 
corresponds to IgG heavy chain. 
 
Astrocytes expressing anchorless PrP do not differ in D-Aspartate transport  
Lipid raft microdomains provide a membrane environment conducive to the 
clustering and interaction of membrane bound proteins. Tg88 transgenic mice express 
anchorless PrP that lacks the glycophosphatidylinositol anchor and thus is no longer 
associated with the membrane and lipid raft, but is secreted (Chesebro et al., 2005). 
Therefore, if similar location of PrP and the EAATs affected L-glutamate transport rates, 
the absence of PrP from the membrane in Tg88 astrocytes should increase the EAAT 
activity. Astrocytes from tg88 neonates were cultured and Na+ dependent transport of 
D-aspartate was measured. At higher concentrations of substrate, tg88 astrocytes did 
not significantly transport D-aspartate differently than WT or PrP KO astrocytes.  The 
Vmax of transport in tg88 astrocytes was also not significantly different from WT or PrP 
KO astrocytes (tg88: 487+ 32, WT: 396+31, PrP KO: 657+44 pmol/min/mg). Though 
 68 
tg88 mice lacked PrP expression on the cell membrane, their transport of substrate did 
not mimic transport observed in KO astrocytes. 
 
Figure 3-4.  
Comparison of D-aspartate transport by EAATs in WT, PrP KO and GPI-/- astrocytes. 
A. EAAT activity was measured in primary astrocytes derived from WT and PrP KO neonatal mice 
cultured 7 days post-harvest. Astrocytes were incubated with 5uM, 10uM, 30uM, 75uM or 150uM 
D-aspartate, a non-metabolized analog of L-glutamate, for 5 minutes. Transport rate at each 
concentration was measured and then fit to the Michaelis Menten equation using non-linear 
regression. Results are averages of data from multiple independent observations. Results show 
faster transport by PrP KO astrocytes.  
B. The Vmax of EAAT-mediated transport for each experiment examining primary astrocytes 7 days 
post harvest is shown. Results show intermediate Vmax values in GPI-/- astrocytes compared to 
WT or PrP KO astrocytes (tg88: 487+ 32, WT: 396+31, PrP KO: 657+44 pmol/min/mg). 
 
DISCUSSION 
Because of the increased EAAT1 activity observed in PrP KO astrocytes, we 
hypothesized that homeostatic levels of EAAT activity are governed by a direct 
interaction between PrP and EAAT1. Both PrP and EAAT1 are membrane-associated 
proteins localized to lipid rafts, a site where they could interact with each other either 
directly or indirectly. For example, the unstructured N-terminal domain of PrP (residues 
22-90) could transiently occlude the ability of glutamate to enter the bowl-shaped EAAT 
and reduce its transport into the astrocyte.  
However, co-immunoprecipitation experiments failed to reveal a strong protein-
protein interaction between PrP and EAAT1 although the experimental approach may 
have prevented an ability to see such an interaction. The lysis conditions used to extract 
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PrP contained an ionic detergent, which may have broken apart a protein-protein 
interaction. It is possible that an interaction between PrP and EAAT1 was weak and 
would not be maintained by the co-immunoprecipitation procedure, as might be 
expected with a transient interaction. Because of previous data based on mRNA 
expression and pharmacology of the PrP KO and WT astrocyte cultures, the majority of 
transport was determined to be by the EAAT1 subtype (Chapter 2). Thus, co-
immunoprecipitation experiments specifically looked for an interaction of PrP with 
EAAT1 and not with EAAT2, which is expressed and functional albeit at markedly lower 
levels compared with EAAT1. The possibility exists that modulation of glutamate 
transport by PrP is subtype specific and that it acts on the less expressed EAAT2.   
It is also possible that a direct interaction between PrP and the EAATs is not 
what modulates transporter efficiency but location does. EAAT1, EAAT2 and PrP are all 
localized to lipid rafts and such an environment may be conducive to the clustering and 
interaction of proteins that serve to regulate levels of EAAT activity. If location was 
indeed what mitigated transport,it was hypothesized that the lack of PrP membrane 
anchoring in tg88 astrocytes would cause transport activity to mimic PrP KO astrocytes.. 
However, in tg88 astrocytes, moderate levels of transport were observed, not different 
from WT or PrP KO astrocytes to which they were compared. However, expression 
levels may explain why tg88 astrocytes demonstrate a phenotype similar to both PrP 
KO and WT astrocytes. Tg88 astrocytes express a secreted PrP but at levels 4-5 times 
less than WT PrP. If a direct interaction between PrP and EAAT1 did occur, possibly it 
could happen between secreted PrP and EAAT1 and thus, the effect of PrP on EAAT 
activity could be PrP dose dependent.  
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ABSTRACT 
Though highly expressed in the central nervous system, the function of prion 
protein (PrP) is unknown. Abnormalities observed in PrP knockout (PrP KO) mice 
suggest a function in L-glutamate mediated neurotransmission. Previously, we 
showed that transport of D-aspartate, a non-metabolized L-glutamate analog, 
through excitatory amino acid transporters (EAATs) was faster in astrocytes from 
PrP knockout (PrP KO) mice than in astrocytes from C57BL/10SnJ wild-type 
(WT) mice. However, since PrP KO mice contained 98.5% sequence identity to 
the WT strain they were compared to, the difference in EAAT activity could be 
attributed to the influence of allelic variants in other genes. Therefore, evaluation 
of EAAT activity in astrocytes harvested from transgenic PrP expressing mice 
with mixed genetic backgrounds was performed. Astrocytes harvested from a 
PrP over-expressing mice (tga20 +/-) did not transport D-aspartate faster than 
PrP null littermates (tga20 -/-). Astrocytes harvested from mice expressing 
hamster PrP only on neurons (tgNSE) did not transport D-aspartate faster than 
hamster PrP over- expressing astrocytes (tg7).  Experiments altering PrP 
expression using PrP silencing in WT astrocytes and PrP transduction in PrP KO 
astrocytes had varied results due to variable expression changes. Taken 
together, these studies suggest WT expression levels of PrP may regulate EAAT 
activity.  
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INTRODUCTION 
  Though evolutionarily conserved, developmentally regulated, and highly 
expressed in numerous tissues, the physiological function of prion protein (PrP) 
is unknown. Mice devoid of PrP expression (PrP KO) develop normally and do 
not exhibit gross abnormalities (Bueler et al., 1992; Manson et al., 1994). 
However, PrP KO mice exhibit several subtle abnormalities suggesting that PrP 
plays a role in cellular homeostasis (reviewed in Chapter one), including 
maintenance of L-glutamate concentrations in the synaptic cleft through 
regulating the activity of excitatory amino acid transporters (EAATs) (Chapter 
Two).  
 PrP KO mice were originally generated through disruption of the Prnp 
gene on chromosome 2 by homologous recombination of embryonic stem (ES) 
cells (Bueler et al., 1992; Manson et al., 1994). In the Edinburgh line of PrP KO 
mice, ES cells from 129/Ola mice were electroporated with recombinant DNA 
containing a neo insertion in the Prnp gene (Manson et al., 1994). Following 
selection, resulting mice were PrP null on a 129/Ola background. Functions of 
PrP could be assessed comparing these mice to 129/Ola wild type mice and 
such studies demonstrated that PrP KO mice had decreased LTP (Manson et al., 
1995) and mitochondrial abnormalities (Miele et al., 2002).  
However, maintenance of the PrP KO line on a 129/Ola background has 
been notoriously difficult and in many laboratories, mice were crossed to better 
breeding lines of mice such as C57BL/10. Despite multiple backcrosses, genetic 
purity of the C57BL/10 strain cannot be re-established and genes immediately 
flanking the Prnp gene locus will be of 129/Ola origin. The PrP KO mice used to 
assess the influence of PrP on EAAT activity were on the C57BL/10 background 
though areas immediately surrounding the Prnp gene locus may have 129/Ola 
genetic determinants (Figure 4-1). Thus, allelic variation in other genes may have 
accounted for the differences observed.  
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Figure 4-1. Schematic of the Prnp gene on chromosome 2 and the area immediately 
surrounding the Prnp gene in wildtype and PrP KO mice.  
 
In an effort to distinguish whether abnormal levels of EAAT activity 
observed in PrP KO astrocytes was due to the lack of PrP expression or flanking 
genes from the 129/Ola strain, activity was measured in PrP expressing and non-
PrP expressing astrocytes. In some experiments, astrocytes were harvested from 
transgenic lines of mice who contain a neo cassette in the Prnp gene but whose 
PrP expression is driven on another chromosome. In other experiments, PrP 
expression was either silenced or induced. 
MATERIALS AND METHODS 
Animals 
 C57BL/10SnJ (WT) mice were purchased from Jackson Labs (Bar Harbor, 
ME). Homozygous PrP knockout (PrP KO) mice on the 129/Ola background 
(Manson et al., 1994) were backcrossed nine times to C57BL/10SnJ mice 
selecting for the PrP KO allele by PCR identification at each cross (Race et al., 
2009).  Homozygous tgNSE (Race et al., 1995), tgGFAP (Raeber et al., 1997) 
and tg7 (Race et al., 1995) mice, originally on a mixed background were 
subsequently backcrossed to PrP KO mice to eliminate mouse PrP gene 
expression, as described (Race et al., 2000). Tga 20 mice (Fischer et al., 1996), 
on a mixed background, were in the process of being backcrossed to PrP KO 
mice. Tga20 mice were bred with PrP KO mice and resulting offspring were 
distinguished by PCR as either heterozygous for the tga20 transgene (+/-) or 
homozygous null mice for the tga 20 transgene (-/-). This generation of 
experimental mice was approximately 93% C57BL/10. 
Astrocyte Cultures 
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Mixed glial cells were harvested from the cortices of WT and KO 1-2 day 
old mice using modifications of the method of McCarthy and de Vellis (McCarthy 
and de Vellis, 1980).  Cortices, with meninges removed, were triturated, plated in 
T-25 flasks with DMEM/F12 (Invitrogen, Carlsbad, CA) containing 15% fetal 
bovine serum (HyClone, Omaha, NE) and maintained in a 5% CO2 incubator at 
37°C. Approximately seven days later, when cultures were confluent, microglia 
and oligodendrocytes were removed from the astrocyte cultures by orbital 
shaking (overnight, 250 rpm). Purified astrocyte cultures were harvested with 
trypsin. For D-aspartate uptake assays, astrocytes were reseeded at 1 x 105 
cells/well in 12 well plates and maintained with fresh media every three days. In 
some experiments, astrocytes were assayed seven days post-seeding, upon 
reaching confluence. 
Na+ dependent D-aspartate uptake assays.   
Confluent astrocytes in 12 well plates were rinsed with a physiological 
transport buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM KCl, 0.4 mM KH2PO4, 
0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH 7.4) and 
pre-incubated at 37 °C for 5 min. Transport rates were determined using 3H-D-
aspartate, which is effectively transported as an EAAT substrate, yet not 
metabolized by cells following uptake (Koch et al., 1999). Transport assays were 
carried out in which uptake was initiated by replacing the preincubation buffer 
with buffer containing 3H-D-aspartate (150µM, 10µCi/ml). Following a five-minute 
incubation, uptake was terminated by 3 consecutive washes with ice-cold buffer. 
Cells were lysed with 0.4N NaOH for 24 hours and analyzed for radioactivity by 
liquid scintillation counting and for protein by the bicinchoninic acid method 
(Pierce, Rockford, IL). Uptake [pmol D-asp/min/mg protein] was calculated and 
corrected for background radiolabel accumulation at 4°C. Previous studies 
confirmed that uptake measured under these conditions was linear with respect 
to time and protein content (Esslinger et al., 2005). Values are reported as mean 
+ SEM pmol/min/mg with each “n” value equaling the number of determinations, 
each done in duplicate. Data was fit to the Michaelis-Menten equation using non-
linear regression (Graph Pad Prism 5, GraphPad Software Inc, La Jolla, CA). 
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Immunoblot 
Purified astrocyte cultures were washed briefly in 5ml cold PBS. 
Astrocytes were lysed by shaking incubation with 1ml cold lysis buffer (5mM Tris 
HCl p.H 7.4, 150mM NaCl, 5mM EDTA, 0.5% Triton X-100, 0.5% deoxycholate, 
1X Protease Inhibitor Cocktail) at 4°C for 5 minutes. Lysates were placed in pre-
cooled 1.5ml centrifuge tubes and centrifuged at 100g for 15 minutes. 
Supernatants were collected and stored at -20°C. Protein concentration was 
quantified using the bicinchoninic acid method (Pierce, Rockford, IL). Cell lysates  
were boiled in 1X Sample Buffer containing Reducing Agent (Invitrogen, 
Carlsbad, CA) for 3 minutes and loaded 16% Tris Glycine gels that were used to 
assess PrP expression, which runs at approximately 33-37 KDa . Gels were run 
for 1 hour at 120V. Proteins were electrophoretically transferred onto a 
polyvinylidene fluoride membrane (37V, O/N). Membranes were blocked in TBS 
with 0.1% tween 20 containing 5% milk. Membranes were probed with antibody 
specific for PrP (D13, 1:5000 (Williamson et al., 1998)) in TBS –tween for one 
hour at room temperature. Following three ten-minute washes with TBS-tween, 
membranes were probed with rabbit anti human (1:3000) diluted in TBS tween 
for one hour at room temperature. Visualization was performed using 
chemiluminescence, according to manufacturer’s recommendations (GE 
Healthcare Life Sciences, Pittsburg, PA).  
Transfection of primary astrocytes with siRNA 
Purified WT and PrP KO astrocytes were plated in 12 well plates at a 
density of 75,000 cells/well. Approximately four days later, when cell appeared 
75% confluent, astrocytes were transfected with 2.5nM, 5nM, 10nM siRNA 
against Prnp (siRNA ID # s72188, Applied Biosystems, Carlsbad, CA ) or 30nM 
scrambled siRNA or 30nM GAPDH siRNA  both of which came with the 
transfection reagent and were used at concentrations recommended by the 
manufacturer. siPORT Amine transfection reagent (Applied Biosystems, 
Carlsbad, CA) was used at 1.5ul per well which was previously determined to be 
a reagent and concentration sufficient to silence GAPDH expression without 
causing visible toxicity to astrocytes. siPORT Amine was diluted in 23.5ul 
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OPTIMEM (Invitrogen, Carlsbad, CA) and incubated for ten minutes at room 
temperature. Meanwhile, siRNA at the indicated concentrations above was 
diluted in OPTIMEM to a final volume of 25ul. Both diluted siRNA and diluted 
transfection reagent were mixed and incubated together at room temperature for 
an additional ten minutes. Complexes were placed onto cells and incubated for 
72 hours in a 37°C, 5% CO2 incubator for 72 hours at which point cells were 
stained harvested for FACS analysis or assayed for Na+ dependent D-aspartate 
transport assays. For immunofluorescent staining, astrocytes were plated onto 
chamber slides and transfection was scaled down to 0.3ul siPORT amine 
transfection reagent in 10ul OPTIMEM and 10ul diluted siRNA. 
Viral transduction of primary astrocytes 
 PrP KO astrocytes were transduced with supernatant from Psi2 cells who 
had been tranfected with retrovirus pSFF or pSFF in which hamster PrP had 
been cloned (graciously given by Suzette Priola, Rocky Mountain Labs, Hamilton 
MT).  Astrocytes were transduced with 500ul stock virus in the presence of 
4ug/ml polybrene. In some wells, astrocytes were treated with 4ug polybrene 
alone. Astrocytes were incubated at 37°C at 5% CO2. Media was completely 
replaced 24 hours after transduction and assessment of PrP expression by 
FACS analysis and D-aspartate transport assays performed 7 days after 
transduction. 
Surface PrP staining and FACS analysis 
 Astrocytes plated in chamber slides were rinsed with PBS 3 times and 
stained live for PrP using 1ug monoclonal antibody D13, specific for PrP diluted 
in PBS with 2% FBS. Following 30 minute incubation at 37°C and 3 washes with 
PBS, astrocytes were fixed in 3.7% formaldehyde for 20 minutes at room 
temperature, washed and permbealized in 0.1% tx-100 and 0.1% sodium citrate 
for 10 minutes at room temperature. Cells were then blocked in 0.1M glycine for 
30 minutes and with NGS/BSA for an additional 30 minutes. Cells were  labeled 
with anti-GFAP (1:1500) (Dako, Carpinteria, CA) conjugated with AlexaFluor568 
goat anti-rabbit IgG (1:3000) (Invitrogen, Carlsbad, CA) to identify astrocytes and 
AlexaFluor488 goat anti-human IgG (1:3000) (Invitrogen, Carlsbad, CA) to 
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visualize PrP staining. Fluorescent images were photographed on an upright 
microscope (Olympus BX51) with a 10X objective using Microsuite Analysis 
software. Control wells stained with secondary antibodies alone did not show 
immunofluorescence.   
 For FACS analysis, astrocytes were rinsed with PBS and removed from T-
25 flasks by incubation with 0.5mM EDTA for 15 minutes at 37°C. PrP staining 
was performed on 200,000 live primary astrocytes using 1 µg monoclonal 
antibody D13, specific for PrP. Following 1 hour incubation at 37°C, cells were 
fixed in 3.7% formaldehyde for 20 minutes, blocked in 0.1M glycine for 30 
minutes and incubated for 1 hour at 22°C with 1 µg AlexaFluor488 goat anti-
human IgG (Invitrogen, Carlsbad, CA). Sister tubes of WT and KO astrocytes 
were fixed, blocked and incubated with AlexaFluor488 goat anti-human IgG 
alone. Data was collected by FACSCanto II flow cytometer (Becton Dickinson, 
San Jose CA) and analyzed using FlowJo (Tree Star, Ashland, OR). 
 
RESULTS 
PrP KO mice contain non-C57BL10 allelic variants 
Though the PrP KO mice used in the experiments described in chapters 
two and three had been serially backcrossed nine times to homozygous 
C57BL10 mice, it was possible that genes immediately adjacent to the Prnp gene 
locus could still be of 129/Ola origin. These genes, which may have differed from 
the WT mice used in experiments, could have also played a role in the increased 
transport observed in PrP KO mice. Therefore, DNA from C57BL10 and PrP KO 
mice were compared using SNP analysis. Non-C57BL10 SNPs were found in 
submitted PrP KO mice only on chromosome two in a 48 mega base pair region 
surrounding the Prnp gene locus. This region of differences contains 556 genes, 
including Slc1a2 which encodes EAAT2. 
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EAAT activity in astrocytes harvested from transgenic mice expressing hamster 
PrP 
 Since genes other than PrP may have contributed to the differences in 
EAAT activity observed between astrocytes harvested from congenic PrP KO 
and WT mice, rescue experiments were performed using mice containing a PrP 
transgene. These transgenic mice were backcrossed to PrP KO mice several 
times.  Importantly, these mice contained the neo insertion in the Prnp gene on 
chromosome 2 and contained the same flanking genes surrounding the Prnp 
gene locus (Figure 4-2).   
 
Figure 4-2. Comparison of astrocytes harvested from mice containing a PrP transgene. 
Transgenic PrP expressing mice contain a neo insertion in the Prnp gene on chromosome 2 as 
well as genes linked to the Prnp gene locus (red). Transgene insertion on chromosome n leads to 
cell-specific PrP expression, ie astrocyte specific or neuron specific (yellow). Trangenic mice 
contain 129/Ola genes (blue) but contain 93-98% genetic identity to the C57BL/10 strain. All 
astrocytes compared for EAAT activity contain the PrP KO gene complex. 
  
 PrP expression was confirmed on astrocytes harvested from hamster PrP 
expressing transgenic lines of mice. Tg-NSE mice express hamster PrP driven 
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by neuron specific promoter, NSE. Tg-7 mice overexpress hamster PrP on 
multiple cell types. As expected, FACS analysis of surface PrP expression 
demonstrated that tg7 and C57BL10 WT astrocytes express PrP whereas Tg-
NSE astrocytes did not express any PrP (Figure 4-3A). Furthermore, levels of 
PrP expression were higher in tg7 astrocytes, consistent with overexpression in 
total brain. Immunoblot of whole astrocyte lysate also revealed overexpression of 
PrP in tg7 astrocytes compared to C57BL/10 WT astrocytes (Figure 4-3B). 
 
 
Figure 4-3. PrP expression on primary astrocytes harvested from PrP-
expressing transgenic mice. 
A. FACS detection of surface PrP expression on astrocytes harvested from C57BL/10, tgNSE 
and tg7 mice. Live primary astrocytes were labeled with D13, specific for PrP. Only C57BL/10 
astrocytes and tg7 astrocytes express PrP. TgNSE astrocytes show the same fluorescent 
intensity as astrocytes labeled with secondary antibody alone. B. PrP immunoblot of lysates 
prepared from WT, tga20 and tg7 purified astrocyte cultures.  
 
The influence of PrP expression on EAAT mediated glutamate transport 
was investigated by measuring EAAT activity in astrocytes harvested from PrP 
expressing transgenic mice. In these experiments, tgNSE astrocytes, tg7 
astrocytes and tgGFAP astrocytes were compared. Tg-GFAP mice express 
hamster PrP driven by the GFAP promoter, and thus, only express PrP on glial 
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cells (Raeber et al., 1997) though with expression in total brain much lower 
compared to WT brains. Sodium dependent transport assays were performed 
using the non-metabolized EAAT substrate, D-aspartate, at 150uM, a 
concentration high enough to delineate activity differences (Chapter 2). As shown 
in Figure 4-4, transport of 150uM D-aspartate was indistinguishable between 
tgNSE astrocytes, tgGFAP astrocytes and tg7 astrocytes (459+26, 372+46, 
451+32 pmol/min/mg respectively, Figure 4-4). Astrocytes were treated with 
0.25mM dbcAMP for ten days to increase EAAT1 and EAAT2 expression and 
thereby increase transport velocities that might distinguish the different 
transgenic lines of astrocytes (Chapter 2). However, treatment of dbcAMP 
treatment, while increasing transport, also did not reveal differences between 
tgNSE, tgGFAP or tg7 astrocytes (597+42, 658+34, 588+94 pmol/min/mg 
respectively, Figure 4-4). Thus, in both untreated and dbcAMP treated 
astrocytes, lack of hamster PrP expression did not change EAAT activity 
compared to low expression of PrP or overexpression of PrP. 
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Figure 4-4. EAAT activity in tgNSE, tgGFAP and tg7 astrocyes. Uptake of 150uM D-aspartate 
was quantified in primary astrocytes cultured from tgNSE, tgGFAP and tg7 mice, which differ in 
levels of hamster PrP expression.  
 
 
EAAT activity in astrocytes harvested from transgenic mice expressing mouse 
PrP 
 Similar experiments attempting to rescue the difference observed between 
PrP KO and WT mice were performed on a line of transgenic mice, tga20, who 
overexpress mouse PrP (Fischer et al., 1996) and were in the process of being 
backcrossed to PrP KO mice. Littermates were either heterozygous at the tga20 
locus and expressed 3-fold higher levels of PrP (tga20 +/-), or were null at the tga 
20 locus and did not express PrP (tga20 -/-). Littermates all contained the Prnp 
null gene complex on chromosome 2 (Figure 4-2). Immunoblot lysates of primary 
astrocytes harvested from tga20 mice demonstrated overexpression of PrP 
compared to WT astrocytes (Figure 4-3B). When transport of 150uM D-aspartate 
was measured in tga20 astrocytes, a difference between tga20 +/- PrP 
expressing and tga20 -/- PrP non-expressing astrocytes was not observed 
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(455+40 vs. 483+22 pmol/min/mg respectively, Figure 4-5). A difference in 
transport velocity was also not observed in dbcAMP treated tga20 +/- vs tga20 -/- 
astrocytes (947+68 vs. 741+62 pmol/min/mg, respectively, Figure 4-5). Thus, 
overexpression of mouse PrP compared to non-expression also did not rescue 
the EAAT activity differences observed between WT and PrP KO astrocytes.  
 
Figure 4-5. EAAT activity in tga20 +- and tga20 -/- astrocytes. Uptake of 150uM D-aspartate 
was quantified in primary astrocytes cultured from tga20 +/- and tga20 -/ astrocytes which 
overexpress or do not express mouse PrP. 
 
EAAT activity in KO astrocytes transduced to express PrP or WT astrocytes with 
silenced PrP expression 
 Usage of transgenic mice to describe EAAT activity as a function of PrP 
expression is still prone to the influence of background genes. Therefore, EAAT 
mediated D-aspartate transport was measured in WT astrocytes whose PrP 
expression was silenced and PrP KO astrocytes induced to express PrP.  
 To rescue the PrP KO phenotype, PrP expression was silenced in WT 
astrocytes by transfecting Prnp specific siRNA, as described in Methods. Levels 
of PrP silencing between experiments were variable and may have depended on 
how the detection method of PrP expression. In some experiments when 
immunoblot and immunostaining of PrP KO astrocytes were employed, silencing 
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specific to siRNA against Prnp compared to a scambled siRNA sequence was 
observed (data not shown). However, FACS analysis showed surface reduction 
of PrP expression independent of the siRNA sequence (Figure 4-6A.). When the 
effect of silencing PrP on EAAT activity was assayed, an increased in D-
aspartate transport was observed in all conditions and was probably the result of 
siRNA transfection (Figure 4-6B).  
 
Figure 4-6. Knockdown of PrP expression following transfection with Prnp specific siRNA. 
A. FACS detection of surface PrP expression on C57BL10 WT astrocytes 72 hours following 
transfection with siRNA against PrP or a scrambled siRNA sequence. Live primary astrocytes 
were labeled with D13, specific for PrP. expression. In this experiment, a reduction in PrP 
expression is observed independent of siRNA sequence. B. Uptake of 150uM D-aspartate was 
quantified in primary PrP KO and WT astrocytes following 72 hours transfection with either siRNA 
against PrP or a scrambled sequence. In all treatments, there was an increase in EAAT activity. 
 
 To rescue PrP expression in PrP KO astrocytes in an attempt to mimic the 
WT phenotype, PrP expression was induced in PrP KO astrocytes and EAAT 
activity was measured. PrP KO astrocytes were transduced in the presence of 
polybrene with retrovirus pSFF in which hamster PrP had been cloned. While 
levels of expression varied experiment to experiment (ranging from 45% - 60%, 
Figure 4-7A), PrP KO astrocytes did express PrP. However, PrP KO astrocytes 
expressing PrP did not exhibit reduced transport compared to PrP KO astrocytes 
not expressing PrP (Figure 4-7B).  
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Figure 4-7. EAAT activity following induction of PrP expression in PrP KO astrocytes. A.  
FACS detection of surface PrP expression 7 days following transduction with pSFF-haPrP in the 
presence of 4ug/ml polybrene (pb). Live primary astrocytes were labeled with D13, specific for 
PrP. expression. Compared to PrP KO astrocytes, 50% transduced astrocytes expressed PrP. B. 
Uptake of 150uM D-aspartate was quantified in PrP KO and WT astrocytes seven days following 
transduction. PrP KO astrocytes transduced to express PrP did not have decreased transport 
compared to untreated KO astrocytes.  
 
DISCUSSION 
 The experiments described in this chapter were aimed at replicating the 
observation that PrP KO astrocytes have higher EAAT activity than WT 
astrocytes. The phenotype observed could not be definitively attributed to PrP 
expression; the mice compared were genetically identical except at chromosome 
2 in the region surrounding the Prnp gene. Here, 129/Ola genes existed in PrP 
KO astrocytes, different than the C57BL10 astrocytes, and thus differences 
observed could be due to the expression of these 129/Ola genes. The gene 
encoding EAAT2, Slc1a2, is located in this region and according to SNP 
analysis, differs between WT and PrP KO mice. Of note, most of the transport in 
the system studied was due to EAAT1 encoded by Slc1a3, located on a 
chromosome 11 and lacking any genetic differences between PrP KO and WT 
mice. 
These experiments used astrocytes harvested from transgenic mice 
whose PrP expression driven by a promoter other than the PrP promoter and 
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whose genome contained the Prnp KO gene complex. If 129/Ola genes flanking 
the Prnp KO gene locus contributed to the differences observed in PrP KO 
versus WT astrocytes, these transgenic mice would have the same 129/Ola 
genes and EAAT would be similar. In experiments examining EAAT activity in 
PrP-expressing transgenic mice, PrP expression did not rescue the WT 
phenotype. The simplest explanation therefore is expression of129/Ola genes in 
the area surrounding the Prnp KO gene locus did play a role in the EAAT activity 
differences observed between WT and PrP KO astrocytes. 
However, there are important caveats to interpreting EAAT activity in PrP 
expressing transgenic mice. The tga20 mice used in this study are of a mixed 
background. Other genes on other chromosomes may be different between the 
lines of mice compared, i.e. Slc1a3 encoding for EAAT1. Furthermore, the PrP 
expressing transgenic mice did not express wild-type levels of PrP. Interestingly, 
the two comparisons that showed similar levels of transport, tgNSE vs tg7 and 
tga20+/- vs. tga20-/-, both compared the lack of PrP expression to the 
overexpression of PrP. Transgene expression can lead to phenotypes by itself 
either due to site of insertion, abnormal expression or overexpression. Tga20 
mice have disturbed T cell development (Jouvin-Marche et al., 2006; Zabel et al., 
2009), increased susceptibility to kainic acid induced seizures and decreased 
synaptic facilitiation and long term potentiation (Rangel et al., 2009). Aggregation 
of PrP has been described in other PrP overexpressing transgenic mice 
(Westaway et al., 1994; Chiesa et al., 2008). The inability, therefore, of the 
rescue experiments to mimic EAAT activity observed in PrP KO and WT mice 
may be due to other reasons unrelated to the Prnp gene and genes flanking the 
region on chromosome two. 
Multiple approaches to understanding the influence of PrP on EAAT 
activity were taken. This includes assessment of another PrP knockout line, 
Zurich PrP 0/0 and the strain used to make the knockout mouse, 129/Ola (data 
not shown). However, because of the same caveats described, interpretation is 
limited. With siRNA and viral transduction experiments, the efficiency of 
manipulation was variable and made comparisons against untreated astrocytes 
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difficult. The best comparison performed was that comparing C57BL/10 wildtype 
and PrP KO mice who share 98.6% genetic identity. The only comparison better 
would be studying the PrP knockout on the 129/Ola background, which will be 
accomplished in future studies.  
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CHAPTER FIVE 
CONCLUSION 
 
 Two questions hover over the fields of prion protein (PrP) biology and excitatory 
amino acid transporter (EAAT) biology: what is the function of PrP and how is EAAT 
activity controlled. Multiple lines of evidence demonstrate that both PrP and the EAATs 
regulate aspects of L-glutamate neurotransmission though a link between them has not 
been demonstrated. The overall aim of this dissertation research was to use PrP KO 
mice as a tool to characterize the influence of PrP on astrocytic EAAT mediated L-
glutamate transport. We found that astrocytes harvested from PrP KO mice displayed 
abnormal EAAT activity that was mediated primarily by the EAAT1 subtype. However, 
the similar localization of the EAATs and PrP to lipid rafts did not appear to control 
EAAT activity nor did overexpression of PrP. Thus, WT PrP expression appeared to 
regulate astrocytic EAAT activity. 
 How might PrP be regulating EAAT activity? EAAT activity is regulated at 
multiple levels: DNA transcription, translation, post-translational modifications and 
localization. At the level of detection, PrP expression did not influence transcriptional 
regulation of EAAT1 or EAAT2 (Chapter 2). PrP expression may influence post-
translational modifications of the EAATs that may subsequently affect functional 
properties of the EAATs. For example, EAAT 1 is glycosylated in the extracellular loop 
of transmembrane helices 3 and 4 (Conradt et al., 1995) and it was not addressed in 
this research whether PrP expression alters the ratio of unglycosylated versus 
glycosylated forms. However, the role of EAAT glycosylations is unknown as both forms 
traffic to the plasma membrane and show similar levels of uptake activity (Conradt et al., 
1995; Raunser et al., 2005). Therefore, the likelihood that PrP affects glycosylation of 
the EAATs is possible though mediating functional outcomes is unlikely. 
 If not through transcriptional regulation or post-translational modification, PrP 
may influence EAAT activity by location. Both PrP and EAATs are localized to lipid rafts 
(Stahl et al., 1987; Butchbach et al., 2004) and such a locale may be conducive to a 
direct or indirect interaction between them. In Chapter 3, we investigated the importance 
of PrP lipid raft localization to EAAT mediated transport by utilizing PrP mutant mice 
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(tg88) which express a soluble form of PrP. Uptake measurements in tg88 astrocytes 
did not demonstrate transport activity that was dependent on lipid raft location. 
However, it is possible that soluble PrP can still bind extracellularly to the EAATs, 
therefore never necessitating membrane localization to control transport. EAAT 
interaction with intracellular proteins in the lipid raft have been identified: GTRAP 41 and 
GTRAP 48 increases EAAT4 activity (Jackson et al., 2001) while GTRAP 3-18 
decreases EAAT 3 activity (Lin et al., 2001). All three EAAT interacting proteins, the 
only ones identified so far, act on neuronal EAATs through binding to the C-terminal 
intracellular domains. It is possible that PrP is an astrocytic EAAT interacting protein 
that decreases EAAT activity through interaction with the extracellular domains on 
EAAT1 and/or EAAT2. 
 The EAATs are also subject to regulation through membrane trafficking and it is 
possible that PrP exerts its influence on EAAT activity by affecting local concentrations 
of EAAT protein on the membrane. Pre-incubation with L-glutamate has been shown to 
alter membrane expression of EAAT1, which was prevented by actin disrupting agents 
(Duan et al., 1999). It has been suggested that EAAT2 can be rapidly internalized by 
clathrin-mediated endocytosis (Zhou and Sutherland, 2004; Susarla and Robinson, 
2008). Alterations in membrane levels of EAAT1/2 may be a mechanism to maintain 
local glutamate concentrations but would require an extracellular sensor (Chaudhry et 
al., 1995). As an extracellular protein, PrP could act as a sensor and mediate the 
internalization of astrocytic L-glutamate transporters in response to L-glutamate 
concentration. Previous studies have suggested that PrP can act as a stress sensor for 
hydrogen peroxide (Krebs et al., 2007) and copper (Rachidi et al., 2003). In our studies, 
EAAT activity was measured by exposing WT and PrP KO astrocytes to varying 
concentrations of D-aspartate. We observed substrate concentration dependant 
differences in EAAT activity between PrP KO and WT astrocytes. Interestingly, 
evidence suggests PrP is also internalized via clathrin-mediated endocytosis, which is 
unusual for a GPI-anchored protein lacking an intracellular sequence necessary for 
interaction with endocytic adaptor proteins. It is possible that internalization of PrP 
requires its interaction with an integral membrane protein that contains a localization 
  93 
sequence for clathrin-mediated endocytosis. Thus, PrP interaction with EAAT 1 and/or 
EAAT 2 may serve to maintain a local glutamate concentration at the synapse.  
 EAAT internalization through clathrin-mediated endocytosis was specifically 
studied on EAAT 2 and whether a similar action of activity dependent internalization of 
EAAT1 is unknown. In our studies, the transporter subtype responsible for the majority 
of transport was EAAT1, which was most likely a result of EAAT1 being highly 
expressed in our cultures. Despite efforts to increase EAAT2 expression through 
dbcAMP treatment and co-culture with neurons, levels of EAAT2 expression were 
typically 10 fold lower than EAAT2 in all cultures. Thus, the contribution of EAAT2 to 
transport in WT and PrP KO astrocytes was overshadowed by the high contribution of 
EAAT1. We hypothesized that the influence of PrP on primary astrocyte L-glutamate 
transport was through modulation of EAAT1 activity and it remains to be seen whether 
similar modulation by PrP would act on EAAT2 and EAAT3 in the synapse. Future 
studies looking at transport in synaptosomes, whose pharmacology profile is EAAT2 
dominant, will address this issue.  
 However, if PrP specifically acted on EAAT1 to decrease L-glutamate transport, 
its contribution to regulating L-glutamate concentrations in vivo would not be 
insignificant.  EAAT1 is expressed throughout the brain though, in contrast to primary 
astrocytes in vitro, its expression is lower than EAAT2 whose expression dominates in 
all areas of the brain except the cerebellum (Danbolt, 2001). The assumption that 
EAAT2 is the most relevant L-glutamate transporter in vivo is most likely due to its high 
expression. For example, quantitative immunoblotting demonstrated that in the 
hippocampus, EAAT2 is four times higher than EAAT1 (Lehre and Danbolt, 1998). Over 
90% EAAT2 activity is immunoprecipitated from crude forebrain extracts of reconstituted 
activity (Haugeto et al., 1996) and the pharmacology profile of synaptosomes is mainly 
EAAT2 (Koch et al., 1999b). Thus, analogous to what we observed in our primary 
astrocyte cultures, expression differences of EAAT1 and EAAT2 might hide functional 
contributions to overall L-glutamate transport. Understanding the contribution of other 
transporters to maintenance of L-glutamate homeostasis is overshadowed by EAAT2 
dominant expression. Interestingly, pharmacological inactivation of EAAT2 did not lead 
to widespread neuronal death as expected, suggesting that other L-glutamate 
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transporters such as EAAT3 and EAAT 1 can be rapidly mobilized to clear L-glutamate 
(Selkirk et al., 2005). 
 The importance of EAAT1 is poorly understood in vivo. EAAT1 is the dominant 
transporter expressed during development in all regions of the brain and its expression 
remains throughout adulthood.  EAAT1 is the primary transporter expressed by 
Bergman glia in the cerebellum and EAAT1 knockout mice suffer from cerebellar ataxia. 
Interestingly, dysfunction in EAAT1 is implicated in schizophrenia (Karlsson et al., 
2009), a disease in which a hypothesized mechanism is decreased glutamate signaling 
(Miyamoto et al., 2005). PrP KO mice suffer from abnormalities that may be related to 
dampened L-glutamatergic neurotransmission including reduced synaptic transmission, 
long term potentiation and poor behavior in learning and memory tasks (Criado et al., 
2005). These observations may be the result of premature clearance of glutamate by 
overactive astrocytic EAATs. 
Does abnormal L-glutamate transport contribute to the synaptic dysfunction 
observed in transmissible spongiform encephalopathies (TSEs)? TSEs are fatal 
neurodegenerative diseases. Several mammalian TSE strains exist, including bovine 
spongiform encephalopathy or “mad cow disease” in cattle, scrapie in sheep and goats, 
chronic wasting disease in deer and elk and Gerstmann Sträussler Scheinker 
syndrome, familial Creutzfeldt-Jacob Disease (CJD), fatal familial insomnia, variant 
CJD, and kuru in humans. Notably, the species barrier usually restricts transmission of 
TSE diseases from one species to another, but as evident with BSE transmission to 
humans, is possible. Fortunately, the difficulty in crossing the species barrier as well as 
increased surveillance in human consumed game and livestock has rendered human 
transmission low; the incidence of disease is one or two cases per million humans. 
Nevertheless, the spread of disease within an infected herd and threat of human 
infection has consequently made an enormous economic impact on the livestock and 
hunting industries. 
TSE strains are unique in the targeted species, incubation time, clinical 
presentation and tissues affected. However, they share common histopathological 
characteristics. Disease manifests itself as grey matter spongiform vacuolation, 
neuronal dropout and gliosis, usually colocalizing with PrPres. PrPres is conformationally 
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distinct from PrP in that it is β-sheet rich and prone to aggregation. PrPres accumulates 
at the cell surface in intracellular vesicles or as diffuse extracellular deposits (Caughey 
et al., 2009). Typically, TSEs are characterized by a long incubation time in which most 
symptoms, in relation to the incubation period, shortly precede death. Spongiform 
vacuolation may be an early morphological marker as neurons are not lost yet but 
vacuoles are formed within them (Moreno and Mallucci, 2010). In mouse models, 
synaptic pathology represents one of the earliest changes seen in the disease (Clinton 
et al., 1993; Fuhrmann et al., 2007; Mallucci et al., 2007) and results in reduced 
synaptic responses and behavioral deficits related to spatial learning (Mallucci et al., 
2007). The disease progresses into ataxia and wasting. In humans, clinical symptoms 
are characterized by cognitive decline, dementia and cerebellar ataxia (Aguzzi et al., 
2008). 
 The causes of synaptic pathology in TSEs are unknown but abnormal EAAT 
activity could be a contributing factor. The direct and indirect vulnerability of neurons to 
PrPres induced damage demonstrates that the disease takes advantage of the 
relationship between neurons and astrocytes. Mice expressing PrP only on neurons are 
susceptible to TSE infection (Race et al., 1995), suggesting that PrP expression on non-
neuronal cells is not necessary for disease. However, neurons secrete soluble factors 
that affect EAAT expression (Gegelashvili et al., 1997; Swanson et al., 1997; Yang et 
al., 2009) as well as present PrPres extracellularly which may cause compromised 
astrocytic EAAT function. Interestingly, mice expressing PrP only on astrocytes are also 
susceptible to TSE (Raeber et al., 1997), demonstrating that neuronal damage from 
infection can come indirectly. Astrocytes are one of the earliest sites of PrPres 
accumulation in the brain (Diedrich et al., 1991) and PrPres toxicity might also cause 
disturbance in astrocytic EAAT activity, thereby perturbing synaptic L-glutamate 
homeostasis. These abnormalities could precede the development of neuropathological 
changes but affect more subtle phenotypes such as altered dendritic spine morphology 
(Fuhrmann et al., 2007) and depressed synaptic responses (Mallucci et al., 2007). 
Gliosis in the terminal stages of disease may lead to reversal of glutamate uptake (Koch 
et al., 1999a) in which the EAATs may act as a site of efflux for cellular L-glutamate. 
Interestingly, increased EAAT1 expression was observed in microglia of patients with 
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CJD and FFI who had long survival periods suggesting that, though not sufficient to 
prevent neurological deterioration, microglial expression of EAAT1 might be 
neuroprotective. If EAAT dysfunction plays a role in pathology of TSE diseases several 
questions would have to be addressed, such as the duration of exposure to TSE, 
whether PrPres accumulation is necessary and whether possible dysfunction is great 
enough to lead to neuronal damage. 
 The function of PrP may be multidimensional, converging on a role maintaining 
synaptic specificity in which activity dependent events are targeted towards appropriate 
neurons and receptors, limiting spillover, excessive activation or premature signal 
termination. The importance of EAATs in controlling glutamate signaling is region 
dependent and thus, PrP’s influence may be most critical in areas where astrocytes 
tightly ensheath nerve terminals. Perhaps in other areas where termination of signal 
operates through diffusion, PrP affects L-glutamate receptor distribution or activation. 
The symptoms and pathology of TSE infection may take advantage of the role of PrP in 
the glutamatergic system starting with a pre-clinical stage characterized by low-level 
synaptic dysfunction and ending with a clinical stage that may be a result of 
excitotoxicity and transporter reversal. Through modulation of EAAT activity and 
glutamate receptor dynamics, the function of PrP may be to maintain an optimal level of 
L-glutamate in the synaptic cleft during all phases of neuronal signaling.  
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